

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MARYLAND  
(SOUTHERN DIVISION)**

HAIMANOT ARAGAW, et al.	*	
Plaintiffs	*	
v.	*	Case No.: 8-21-cv-01739- CBD
LEROY H. CARHART, JR., M.D., et al.	*	
Defendants	*	

**PRELIMINARY RULE 26(a)(2) EXPERT WITNESS DISCLOSURES ON BEHALF OF  
DEFENDANTS LEROY H. CARHART, JR., M.D., ABORTIONCLINICS.ORG a/k/a  
ABORTION CLINICS AND/OR ACO INCORPORATED, d/b/a  
ABORTIONCLINICS.ORG AND/OR ABORTIONCLINICS**

Defendants Leroy H. Carhart, Jr., MD and AbortionClinics.org, a/k/a AbortionClinics and/or ACO Incorporated and ACO Incorporated, d/b/a AbortionClinics.Org, Inc. and/or AbortionClinics, by and through their attorneys Mary Alane Downs, Steffany K. Bender and Downs Ward Bender Herzog & Kintigh, P.A. and pursuant to Federal Rule 26(a)(2) and the Scheduling Order discloses the following expert witnesses that may be called at trial as follows:

**PRELIMINARY STATEMENT**

The Defendants offer this list of expert witnesses as a Preliminary Designation of Expert Witnesses who may be called at trial. Discovery in this matter is on-going. Consequently, the Defendants are not in a position to make a final determination regarding expert witnesses. The Defendants reserve the right to identify additional expert witnesses after completing the discovery depositions of all of the Plaintiffs’ expert witnesses and fact witnesses.

The language employed in this Preliminary Designation of Expert Witnesses is a lawyer’s summary of the experts’ opinions as have been understood by this law firm and is not intended to

express the exact wording nor the totality of these experts' opinions. This Preliminary Designation of Expert Witnesses represents counsel's attempt to synthesize and summarize opinions that are anticipated at trial. These experts may alter or revise this wording and/or modify any of the presently expressed opinions as indicated.

**PRELIMINARY EXPERT DESIGNATION**

The Defendants reserve the right to call the following individuals to testify at the time of trial of the above-captioned action:

**Matthew F. Reeves, M.D.**

1120 19<sup>th</sup> Street, N.W., Suite 800

Washington, D.C. 20036

*Specialty: Obstetrics and Gynecology/Reproductive Medicine*

Dr. Reeves is a licensed physician and is board certified in obstetrics and gynecology. Dr. Reeves has experience and has provided consultation, care, and treatment in the field of obstetrics and gynecology within five (5) years of the date of the circumstances giving rise to this claim. Dr. Reeves has reviewed the Complaint, medical records, and other relevant material pertaining to the care and treatment rendered to Ms. Haimanot Aragaw in the above-captioned action. It is anticipated that Dr. Reeves will review additional pertinent material as it becomes available through the discovery process in this matter. Dr. Reeves's testimony will address the issues of standard of care, causation and damages. It is anticipated that Dr. Reeves will testify that the agents (actual and/or apparent), servants and employees of AbortionClinics.org, a/k/a AbortionClinics and/or ACO Incorporated and ACO Incorporated, d/b/a AbortionClinics.Org, Inc. and/or AbortionClinics, including but not limited to Dr. Leroy Carhart, Jr., complied with accepted standards of care with regard to his involvement in Ms. Aragaw's case. It is further anticipated that Dr. Reeves will testify that no act or omission on the part of Dr. Carhart was a proximate cause of injury to Mrs. Aragaw as claimed.

Ms. Aragaw presented to Abortion Clinics (ACO Incorporation) on May 20, 2020, for a planned abortion of a 24 week/3 day gestational age fetus. The abortion was planned due to the fetus testing positive for the chromosomal abnormality trisomy 21 (Down Syndrome). On May 15, 2020, Ms. Aragaw signed each page of an extensive informed consent document which identified known and material risks of the procedure. It is anticipated that Dr. Reeves will testify that the informed consent process was completed appropriately and within accepted standards of care. On May 20, 2020, Ms. Aragaw was seen for insertion of laminaria. The laminaria placement was without complication. Ms. Aragaw was instructed to return the following day for the planned extraction. On May 21, 2020, Ms. Aragaw arrived at the clinic at approximately 9:11 am. Artificial rupture of membranes was accomplished at 9:57 am. Ms. Aragaw tolerated removal of the laminaria but began to have bleeding. Ultrasound evaluation revealed a low lying placenta. Upon further evaluation, the decision was made to continue with dilation and evacuation. It is anticipated that Dr. Reeves will testify that this was appropriate and within accepted standards of care. As the procedure continued, Ms. Aragaw reported being uncomfortable and with some pain. Dr. Carhart was called to assist. Ultimately, the procedure was stopped due to concern for possible perforation and Ms. Aragaw was transported to Shady Grove Adventist Hospital for further management. It is anticipated that Dr. Reeves will testify that this was appropriate and within accepted standards of care. While at Shady Grove, Ms. Aragaw underwent an exploratory laparotomy which revealed a uterine fundus avulsion from 2 to 10 o'clock around the circumference of the cervix with incomplete surgical abortion and injury to the appendix. Pathologic evaluation confirmed a diagnosis of placenta accreta. Ms. Aragaw was discharged from Shady Grove Adventist Hospital on May 25, 2020.

It is anticipated that Dr. Reeves will testify that the complication encountered during Ms. Aragaw's procedure is a recognized complication of the procedure itself and does not represent a breach from accepted standards of care on the part of the health care providers caring for Ms. Aragaw. In addition, it is anticipated that Dr. Reeves will offer testimony regarding the general medical issues relevant to this matter. Dr. Reeves's opinions will be based upon his education, training, and experience, as well as his review of the medical records and other relevant material produced during discovery. It is anticipated that Dr. Reeves's opinions will be expressed to a reasonable degree of medical probability. To the extent necessary and/or appropriate, it is anticipated that Dr. Reeves experts will respond to and rebut the opinions of the Plaintiffs' expert witnesses. Specifically, but without limitation, it is anticipated that Dr. Reeves will respond to and rebut each of the allegations of negligence asserted on behalf of the Plaintiffs by C. Brent Boles, M.D. and/or Forest Owen Smith, M.D. Specifically, but without limitation, it is anticipated that Dr. Reeves will respond to and rebut any assertion that Dr. Carhart and/or the agents (actual and/or apparent), servants and employees of AbortionClinics.org, a/k/a AbortionClinics and/or ACO Incorporated and ACO Incorporated, d/b/a AbortionClinics.Org, Inc. and/or AbortionClinics breached the standard of care in the informed consent process or in the performance of the procedure or in the management of Ms. Aragaw once the complication was encountered. Discovery in this matter is on-going and neither Dr. Boles, Dr. Smith nor any other of the experts identified by the Plaintiffs have been deposed. To the extent that the Plaintiffs' designation of expert witnesses lacks specificity with regard to any asserted breach from accepted standards of care and/or any alleged mechanism of injury, the Defendant respectfully reserves the right to supplement this disclosure as necessary.

Upon request, Dr. Reeves will be made available for deposition at a mutually convenient date and time. Dr. Reeves has previously provided a Certificate of Meritorious Defense and written report which are incorporated by reference as if fully set forth herein. A copy of his *curriculum vitae* is attached as **Exhibit 1** and is incorporated by reference as if fully set forth herein. Additional information pertaining to Dr. Reeves' testimonial history and fee schedule will be provided.

**Jennifer Lanier Payne, M.D.**

University of Virginia  
Department of Psychiatry and Neurobehavioral Sciences  
2955 Ivy Road, Suite 210  
Charlottesville, Virginia 22903  
*Specialty: Psychiatry and Neurobehavioral Sciences*

Dr. Payne is a board-certified Psychiatrist and Neurologist who specializes in mood disorders. Dr. Payne currently serves as a Professor of Psychiatry and Neurobehavioral Sciences and Vice Chair of Research, Psychiatry and Neurobehavioral Sciences at the University of Virginia. Dr. Payne also serves on the part-time faculty of the Johns Hopkins School of Medicine as an Associate Professor of Psychiatry and Behavioral Sciences and an Associate Professor of Gynecology and Obstetrics. Dr. Payne has reviewed the Complaint, medical records, and other relevant material pertaining to the care and treatment rendered to Ms. Haimanot Aragaw in the above-captioned action. It is anticipated that Dr. Payne will review additional pertinent material as it becomes available through the discovery process in this matter. Dr. Payne's testimony will address the issues of causation and damages. In addition, it is anticipated that Dr. Payne will offer testimony regarding the general medical/psychological issues relevant to this matter. Dr. Payne's opinions will be based upon her education, training, and experience, as well as her review of the medical records and other relevant material produced during discovery. Dr. Payne has reviewed the medical records obtained to date and will opine as to Ms. Aragaw's pre- and postoperative

psychiatric condition as documented therein. Dr. Payne will testify that Ms. Aragaw's psychiatric and mental health conditions were not proximately caused by the alleged negligence. Dr. Payne may also testify regarding Ms. Aragaw's current and future care needs. She may also perform an independent medical evaluation of Ms. Aragaw and provide additional opinions based on her examination.

It is anticipated that Dr. Payne's opinions will be expressed to a reasonable degree of medical probability. To the extent necessary and/or appropriate, it is anticipated that Dr. Payne will respond to and rebut the opinions of the Plaintiffs' expert witnesses. Discovery in this matter is on-going and the experts identified by the Plaintiffs have not been deposed. To the extent that the Plaintiffs' designation of expert witnesses lacks specificity with regard to any claimed injuries, the Defendants respectfully reserve the right to supplement this disclosure as necessary.

Upon request, Dr. Payne will be made available for deposition at a mutually convenient date and time. Her qualifications, opinions, and the bases of her opinions are further detailed in her written report and CV, which are attached collectively to the designation of expert witnesses submitted on behalf of Dr. Anh-Chi Dang Do, M.D. and are incorporated herein by reference along with a testimonial list and her fee schedule.

**Sandra E. Reznik, M.D., Ph.D.**

Department of Pathology  
Department of Obstetrics and Gynecology and Women's Health  
Albert Einstein College of Medicine  
Montefiore Medical Center  
Bronx, New York 10461  
*Specialty: Pathology*

Dr. Reznik is a pathologist focusing on obstetrics and gynecology. Dr. Reznick currently serves as an Associate Professor in the Department of Pathology and Department of Obstetrics and Gynecology and Women's Health at the Albert Einstein College of Medicine. Dr. Reznik also

serves as the Director of the Perinatal Pathology Section in the Department of Pathology at the Montefiore Medical Center as well as a Professor in the Department of Pharmaceutical Sciences at St. John's University.

Dr. Reznik will testify regarding causation and damages based on her review of Ms. Aragaw's medical records from Shady Grove Medical Center, the pathology slides, and other pertinent materials, including the depositions of the parties and other fact witnesses. Dr. Reznik will opine that the pathology slides contain evidence of placenta accreta and acute and chronic inflammation. Dr. Reznik will also respond to the opinions offered by Plaintiffs' expert witnesses. Dr. Reznik's opinions will be offered to a reasonable degree of medical probability. Her qualifications, opinions, and the bases of her opinions are further detailed in her written report and CV, which are attached collectively to the designation of expert witnesses submitted on behalf of Dr. Anh-Chi Dang Do, M.D. and are incorporated herein by reference along with a testimonial list and her fee schedule. Because discovery and investigation are ongoing, Defendants Leroy H. Carhart, Jr., MD and AbortionClinics.org, a/k/a AbortionClinics and/or ACO Incorporated and ACO Incorporated, d/b/a AbortionClinics.Org, Inc. and/or AbortionClinics reserve the right to supplement this designation. Dr. Reznik will be made available for deposition at a mutually convenient time, date and location upon request and following the depositions of Plaintiffs' experts.

**Anthony C. Sciscione, D.O.**

The Delaware Center for Maternal & Fetal Medicine  
Abby Medical Center  
One Centurian Drive, Suite 312  
Newark, Delaware 19713

*Specialty: Obstetrics and Gynecology*

Dr. Sciscione is a Doctor of Osteopathic Medicine who specializes in obstetrics and gynecology. Following his graduation from the University of New England College of Osteopathic

Medicine, Dr. Sciscione completed an internship in Obstetrics and Gynecology at St. Joseph's Hospital and later became a Resident in Obstetrics and Gynecology at the Medical Center of Delaware. Dr. Sciscione also served as a Fellow in Maternal-Fetal Medicine at the Johns Hopkins Medical Institutions. Dr. Sciscione currently serves as a Professor in Obstetrics and Gynecology at the Jefferson Medical College.

Dr. Sciscione will testify regarding the causation and damages based on his review of Ms. Aragaw's medical records, the imaging, and other pertinent materials, including the depositions of the parties and other fact witnesses. Dr. Sciscione's opinions will be offered to a reasonable degree of medical probability. His qualifications, opinions, and the bases of his opinions are further detailed in his written report and CV, which are attached collectively to the designation of expert witnesses submitted on behalf of Dr. Anh-Chi Dang Do, M.D. and are incorporated herein by reference along with a testimonial list and her fee schedule. Dr. Sciscione charges \$350/hour for all of his medical-legal work.

Dr. Sciscione will opine that based on her medical records and clinical presentation, Ms. Aragaw would have more likely than not required hysterectomy and that her claimed injuries were not proximately caused by any negligence on the part of Defendants. Dr. Sciscione will also respond to the opinions offered by Plaintiffs' expert witnesses. Because discovery and investigation are ongoing, the Defendants reserve the right to supplement this designation. Dr. Sciscione will be made available for deposition at a mutually convenient time, date and location upon request and following the depositions of Plaintiffs' experts.

**Tom F. Grogan, C.F.E**  
Victoria Business Center  
1489 Baltimore Pike, Suite 211  
Springfield, Pennsylvania 19064  
*Specialty: Economics*



Mr. Grogan is a graduate of St. Joseph's University and an economist. Mr. Grogan will testify regarding the extent of economic damages allegedly suffered by Plaintiffs, including the present value of any future medical care claimed by Plaintiffs. Mr. Grogan's qualifications are detailed in his CV, which are attached to the designation of expert witnesses submitted on behalf of Dr. Do and are incorporated herein by reference, along with his fee schedule. Because Plaintiffs have not provided any details regarding future care, Mr. Grogan cannot prepare a report regarding his opinions at this time. Because discovery and investigation are ongoing, Defendant reserves the right to supplement this designation and provide a report should Plaintiffs make a claim for future medical expenses.

**ADDITIONAL DISCLOSURE**

The Defendants reserve the right to rely upon, elicit hybrid fact/expert testimony and/or call as their own witness, any of the Plaintiff's treating medical care providers concerning causation and damages, as well as their own care and treatment of Plaintiff and any opinions formed in connection therewith.

The Defendant reserves the right to rely upon, elicit expert testimony and/or call as their own expert witness, any expert designated by any other party to this action, including but not limited to any and all standard of care, causation and/or damages expert witnesses designated by the co-defendant, regardless of whether such designation is subsequently withdrawn. Specifically, the Defendants reserves the right to call as their own expert witness the following individuals:

1. **Philip D. Darney, M.D., MSc**  
ZSFG Division OB/GYN  
1001 Potrero Avenue  
San Francisco, California 94110  
*Specialty: Preventive medicine and Obstetrics and Gynecology*

2. **Shelley Sella, M.D.**


427 62<sup>nd</sup> Street

Oakland, California 94609

*Specialty: Obstetrics and Gynecology*

With regard to each of the above-named expert witnesses, the Defendants incorporate by reference the Expert Witness Disclosure and accompanying materials/exhibits submitted on behalf of Defendant Anh-Chi Dang Do, M.D. as if fully set forth herein.

Respectfully submitted,



---

Mary Alane Downs, Esquire (#03580)

Steffany K. Bender, Esquire (#27615)

Downs Ward Bender Herzog & Kintigh, PA

Executive Plaza III, Suite 400

11350 McCormick Road, Suite 400

Hunt Valley, Maryland 21031

(410) 584-2800 Office

(410) 584-2020 Fax

[madowns@downs-ward.com](mailto:madowns@downs-ward.com)

[skbender@downs-ward.com](mailto:skbender@downs-ward.com)


*Attorneys for Defendants, Leroy H. Carhart, Jr.,  
M.D., AbortionClinics.org, a/k/a AbortionClinics  
and/or ACO Incorporated and ACO Incorporated,  
d/b/a AbortionClinics.org and/or AbortionClinics*

**CERTIFICATE OF SERVICE**

I HEREBY CERTIFY that on this 26<sup>th</sup> day of May, 2022, a copy of the foregoing **Preliminary Rule 26(a)(2) Designation of Expert Witnesses** on behalf of Defendants, Leroy H. Carhart, Jr., M.D., AbortionClinics.org, a/k/a AbortionClinics and/or ACO Incorporated and ACO Incorporated, d/b/a AbortionClinics.org and/or AbortionClinics, was filed with the Clerk of the Court using the CM/ECF system and made available to:

Robert R. Michael, Esquire  
Shadoan, Michael & Wells, LLP  
108 Park Avenue  
Rockville, Maryland 20850  
*Attorneys for Plaintiffs*

Neal M. Brown, Esquire  
Waranch & Brown, LLC  
1301 York Road, Suite 300  
Lutherville, Maryland 21093  
*Attorney for Defendant, Anh-Chi Dang Do,  
M.D.*



---

Mary Alane Downs, Esquire (#03580)  
Steffany K. Bender, Esquire (#27615)  
Downs Ward Bender Herzog & Kintigh, PA  
Executive Plaza III, Suite 400  
11350 McCormick Road, Suite 400  
Hunt Valley, Maryland 21031  
(410) 584-2800 Office  
(410) 584-2020 Fax  
[mardowns@downs-ward.com](mailto:mardowns@downs-ward.com)  
[skbender@downs-ward.com](mailto:skbender@downs-ward.com)  
*Attorneys for Defendants, Leroy H. Carhart, Jr.,  
M.D., AbortionClinics.org, a/k/a AbortionClinics  
and/or ACO Incorporated and ACO Incorporated,  
d/b/a AbortionClinics.org and/or AbortionClinics*

**CURRICULUM VITAE**

Name: Matthew F. Reeves Citizenship: United States of America  
Business phone: 202-844-2004 E-mail: reeves@dupontclinic.com  
Business address: 1120 19<sup>th</sup> Street NW, Suite 800, Washington, DC 20036, USA

**EDUCATION AND TRAINING**

University of Pennsylvania, Philadelphia, PA Bachelor of Arts, Physical Anthropology (cum laude)	1989-1993
University of Pennsylvania, Philadelphia, PA Post-Baccalaureate Pre-Medicine	1993-1995
Harvard Medical School, Boston, MA Doctor of Medicine	1995-1999
University of California, San Francisco Resident, Obstetrics and Gynecology	1999-2003
University of California, San Francisco, Department of Radiology Clinical Fellow, Diagnostic Ultrasound	2003-2004
University of California, San Francisco, Department of Epidemiology & Biostatistics Certificate in Advanced Training in Clinical Research	2003-2004
University of Pittsburgh School of Medicine, Pittsburgh, PA Clinical Fellow, Family Planning & Contraceptive Research	2004-2006
University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA Master of Public Health	2004-2006

**CURRENT POSITIONS AND APPOINTMENTS**

Consultants in Obstetric and Gynecologic Ultrasonography and Surgery, PLLC, Washington, DC Executive Director, DuPont Clinic	2016-present
Celestial Life Sciences, LLC, Washington, DC Chief Executive Officer	2018-present
Stanford University School of Medicine, Stanford, CA Adjunct Clinical Associate Professor of Obstetrics and Gynecology	2015-present
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD Adjunct Associate Professor of Population, Family, and Reproductive Health	2015-present
George Washington University School of Medicine and Health Sciences, Washington, DC Clinical Associate Professor of Obstetrics and Gynecology	2020-present

**CURRENT HOSPITAL PRIVILEGES**

George Washington University Hospital, Washington, DC Hospital privileges, obstetrics and gynecology	2017-present
Sibley Memorial Hospital, Johns Hopkins Health System, Washington, DC Hospital privileges, obstetrics and gynecology	2016-present

**PAST POSITIONS AND APPOINTMENTS**

National Abortion Federation, Washington, DC Medical Director	2013-2018
--	-----------

## Curriculum Vitae

Matthew F. Reeves, MD, MPH

WomanCare Global, San Diego, CA Chief Medical Officer	2010-2014
Washington Hospital Center, Washington, DC Hospital privileges, gynecology	2013-2020
Research Mentor, Fellowship in Family Planning	2010-2018
Eastern Virginia Medical School, Arlington, VA Medical Officer, CONRAD	2009-2010
Assistant Professor, Obstetrics and Gynecology	2009-2010
University of Pittsburgh School of Medicine, Pittsburgh, PA Department of Obstetrics, Gynecology, and Reproductive Sciences	
Clinical Instructor	2004-2006
Assistant Professor	2006-2009
Director, Center for Family Planning Research	2006-2008
Associate Director, Global Health Program in Reproductive Sciences	2007-2009
Associate Director, Fellowship in Family Planning	2008-2009
Clinical and Translational Sciences Institute Assistant Professor	2008-2009
Magee-Womens Research Institute, Pittsburgh, PA Assistant Investigator	2006-2009
Magee-Womens Hospital, Pittsburgh, PA Staff physician, obstetrics and gynecology	2004-2009
Staff physician, ultrasound	2006-2009
Planned Parenthood of Metropolitan Washington, District of Columbia Contract physician	2009-2018
Planned Parenthood Western Pennsylvania, Pittsburgh, PA Contract physician	2004-2009
Women's Health Specialists, Sacramento, CA Contract physician	2003-2004
Planned Parenthood Golden Gate, San Francisco, CA Contract physician	2001-2004
University of California, San Francisco Administrative Chief Resident, Obstetrics and Gynecology	2002-2003

---

 CERTIFICATION AND LICENSURE
 

---

American Board of Obstetrics & Gynecology, Diplomate	2008-present
District of Columbia Medical License	2009-present
District of Columbia Controlled Substance License	2009-present
Virginia Medical License	2009-present
Maryland Medical License	2009-present
Maryland Controlled Dangerous Substances Registration	2013-present
Controlled Substance Registration, U.S. Drug Enforcement Administration	2001-present
Pennsylvania Medical License	2004-2010
California Medical License	2001-2004
Hawaii Medical License	2002-2004
United States Medical License Examination, Steps I, II, & III, completed	1997-2000

Curriculum Vitae

Matthew F. Reeves, MD, MPH

---

**MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES**

---

American College of Obstetricians & Gynecologists, Fellow	2008-present
Society of Family Planning, Fellow	2008-present
Physicians for Reproductive Health	2004-present
European Society of Contraception and Reproductive Health	2009-present
Fédération Internationale des Associés Professionnels de l'Avortement et de la Contraception (FIAPAC)	2010-present
International Society of Ultrasound in Obstetrics and Gynecology	2011-present
American Institute of Ultrasound in Medicine	2002-2007, 2016-present
Association of Reproductive Health Professionals	2002-2018
Society for Medical Decision Making	2005-2009

---

**HONORS**

---

Top Doctor, Washingtonian Magazine	2020
Daniel R. Mishell, Jr, MD, Outstanding Article Award, co-author	2015
<i>Obstetrics and Gynecology</i> Roy M. Pitkin Award, co-author	2010
<i>Contraception</i> Outstanding Article Award, co-author	2010
Gynecologic Fellow Teaching Award (Residents of Magee-Womens Hospital)	2006
Top 10% of Reviewers for <i>Obstetrics &amp; Gynecology</i>	2005, 2008
Wyeth New Leaders Award (Association of Reproductive Health Professionals)	2003, 2004, 2005
Warren-Whitman-Richardson Fellowship Award (Harvard Medical School)	2003-2004
Paul Dudley White International Research Fellowship (Harvard Medical School)	1998
Monbusho Fellowship for Young Foreign Researchers (National Institutes of Health)	1996
Graduation cum laude, University of Pennsylvania	1993
Dean's List, University of Pennsylvania	1990-1991
Distinction in Major, Physical Anthropology, University of Pennsylvania	1993

---

**PROFESSIONAL ACTIVITIES AND SERVICE**

---

**Committees and Boards**

DKT International	
Board of Directors	2019-present
Fédération Internationale des Associés Professionnels de l'Avortement et de la Contraception (FIAPAC)	
Board of Directors	2018-present
American College of Obstetricians & Gynecologists, Washington, DC	
Committee member, Clinical Practice Guidelines - Gynecology	2021-present
Committee member, ACOG Online Learning in Ob-Gyn Advisory Committee	2021-present
National Medical Committee, Planned Parenthood Federation of America	
Immediate Past Chair (ex officio)	2020-present
Chair	2018-2020
Vice Chair	2016-2017
Executive committee member	2014-2020
Committee member	2012-2020
Ad Hoc Analgesia and Sedation Work Group	2015-2017
<i>BMJ Sexual &amp; Reproductive Health</i>	
Editorial Advisory Board	2019-present
Contraceptive Clinical Trials Network, NICHD	
Data and Safety Monitoring Board	2017-present

## Curriculum Vitae

Matthew F. Reeves, MD, MPH

National Abortion Federation Scientific Committee	2013-present
Society of Family Planning Abortion Clinical Research Network Working Group	2019-present
Large Research Grant Review Committee	2017
Nominations committee	2008
Guttmacher Institute Institutional Review Board	2011-2019
North America Forum on Family Planning Scientific Abstract Committee	2016, 2017
Meeting Planning Committee	2016, 2018
Fellowship in Family Planning Planning Committee, FFP Global Health Placements Workshop	2011
Fellowship site evaluator	2009
<i>Ad hoc</i> committee to revise the FFP General and Special Requirements	2008
Association of Reproductive Health Professionals Peer Review Committee, Reproductive Health 2009	2009
Peer Review Committee, Reproductive Health 2010	2010
University of Pittsburgh School of Medicine Residency Admissions Committee, Dept of Obstetrics, Gynecology & Repro. Sciences	2007-2009
Magee-Womens Hospital of UPMC Pharmacy & Therapeutics Committee	2007-2009
UCSF School of Medicine Graduate Medical Education Committee	2002-2003
Residency Council, Dept of Obstetrics, Gynecology & Reproductive Sciences	2002-2003
Residency Admissions Committee, Dept of Obstetrics, Gyn. & Repro. Sciences	2000-2003
Harvard Medical School Financial Aid Committee	1995-1999
<u>ADVISORY AND CONSULTING POSITIONS</u>	
Bill and Melinda Gates Foundation Consultant, new contraception development	2020-present
Carafem, Washington, DC Medical Advisor	2015-present
GenBioPro Senior Medical Consultant	2019-present
Sebela Pharma Medical Advisor	2019-present
Simple Health Medical Advisor	2019-present
Daré Biosciences, Inc. Consultant	2019-present
ContraMed, LLC Consulting Medical Director	2013-2018
Later Abortion Initiative, Ibis Reproductive Health Advisory board member	2015-2018
Safe2choose	

Medical Advisor

2017-2018

ADVISORY MEETINGS (ONE-TIME)

Subject Matter Expert, Subspecialty Practice Analysis SME Panel 1, Complex Family Planning. American Board of Obstetrics and Gynecology, Dallas, TX. 10-11 February 2020.

Acknowledged information source. National Academies of Sciences, Engineering, and Medicine. 2018. The safety and quality of abortion care in the United States. Washington, DC: The National Academies Press. <https://doi.org/10.17226/24950>.

Invited participant, WHO Technical Consultation: Implementing policy recommendations for expanding family planning coverage and access. Chateau de Penthes, Geneva. 15-16 November 2012.

Invited participant, WHO Technical Consultation: Research leads to widen contraceptive choice. Chateau de Penthes, Geneva. 13-14 November 2012.

Invited participant, WHO Technical Consultation on Hormonal Contraception and HIV, World Health Organization, Geneva. 31 January - 1 February 2012.

Invited participant, WHO Meeting to review funding needs arising from the recommendations of the Technical consultation on Hormonal contraception and HIV, World Health Organization, Geneva, 2 February 2012

OTHER ADVISORY POSITIONS

Scientific Advisory Committee. *Early Abortion Training Workbook (Fifth Edition)*. UCSF Bixby Center for Global Reproductive Health. San Francisco, CA, 2016.

Advisory committee member, "Immediate Initiation of Progestin Contraceptives in First-Trimester Medical Abortion: A Randomized Trial" (GHP study 1009), Gynuity Health Project, 2013.

Advisory committee member. Contraceptive Development Advocacy Project, UCSF Bixby Center for Global Reproductive Health, 2012-2016.

Scientific Advisory Committee. *Early Abortion Training Workbook (Fourth Edition)*. UCSF Bixby Center for Global Reproductive Health. San Francisco, CA, 2012.

Technical Advisory Group member. Near Term Advocacy Platform for Family Planning, Health Policy Project, 2011-2013

Steering Committee Member, CAMI (Coalition Advancing Multipurpose Innovations), 2010-2012.

Chief Faculty Advisor. "Ultrasound in Abortion Care" CD-ROM. Planned Parenthood Federation of America & National Abortion Federation, joint project, 2005-2007.

Physician Advisory Board Member. Endo Pharmaceutical, 2005-2006.

Advisory Committee Member. *Early Abortion Training Workbook (Second Edition)*. UCSF Center for Reproductive Health Research & Policy. San Francisco, CA, 2004-2007.

Journal Reviewer

<i>Obstetrics and Gynecology</i>	2003-present
<i>Contraception</i>	2006-present
<i>BMJ Sexual &amp; Reproductive Health</i>	2019-present
<i>International Journal of Gynecology and Obstetrics</i>	2015
<i>Journal of Pediatric and Adolescent Gynecology</i>	2006-2009
<i>American Journal of Obstetrics and Gynecology</i>	2008
<i>American Journal of Human Genetics</i>	2009



*Ultrasound in Obstetrics and Gynecology*

2009

Other

EARTH (Environmental Awareness and Recycling To improve Harvard)

Director/Organizer, Harvard Medical School

1995-1997

---

PUBLICATIONS

---

REFEREED ARTICLES (View [all citations](#) here)

1. Shakir-Reese J, Ye P, Perritt J, Lotke P, **Reeves MF**. A Factorial-Design Randomized Controlled Trial Comparing Misoprostol alone to Dilapan with Misoprostol and Comparing Buccal to Vaginal Misoprostol for Same-day Cervical Preparation prior to Dilatation & Evacuation at 14 weeks 0 days to 19 weeks 6 days gestation. *Contraception*. 100(5): 445-50, 2019 December. PMID 31520608. [<https://doi.org/10.1016/j.contraception.2019.09.001>]
2. **Reeves MF**, Katz B, Canela JM, Hathaway MJ, Tal MG. A randomized comparison of a novel nitinol-frame low-dose-copper intrauterine contraceptive and a copper T380S intrauterine contraceptive. *Contraception*. 95(6): 544-8, 2017 June. PMID 28495299. (2 citation) [<http://dx.doi.org/10.1016/j.contraception.2017.04.002>]
3. Casey FE, Ye PP, Perritt JD, Moreno-Ruiz NL, **Reeves MF**. Same-Day Mifepristone and Misoprostol Compared to Misoprostol only for Cervical Preparation prior to Second-Trimester Surgical Abortion. *Contraception*. 94(2): 127-33, 2016 August. PMID 26948184. (11 citations) [<http://dx.doi.org/10.1016/j.contraception.2016.02.032>]
4. **Reeves MF**, Zhao Q, Secura GM, Peipert JF. Risk of unintended pregnancy based on intended compared to actual contraceptive use. *American Journal of Obstetrics and Gynecology*. 215(1): 71.e1-6, 2016 July. PMID 26805610. (17 citations) [<http://dx.doi.org/10.1016/j.ajog.2016.01.162>]
5. **Reeves MF**, Monmaney JA, Creinin MD. Predictors of Uterine Evacuation following Early Medical Abortion with Mifepristone and Misoprostol. *Contraception*. 93(2): 119-25, 2016 February. PMID 26285178. (5 citations) [<http://dx.doi.org/10.1016/j.contraception.2015.08.010>]
6. Grossman D, White K, Harris L, **Reeves M**, Blumenthal P, Winikoff B, Grimes D. Continuing pregnancy after mifepristone and "reversal" of first-trimester medical abortion: a systematic review. *Contraception*. 92(3): 206-11, 2015 September. PMID 26057457. (27 citations) [<http://dx.doi.org/10.1016/j.contraception.2015.06.001>]
7. Bednarek PH, Creinin MD, **Reeves MF**, Cwiak CA, Espey E, Jensen JT. Prophylactic ibuprofen does not improve pain with IUD insertion: a randomized trial. *Contraception*. 91(3): 193-7, 2015 March. PMID 25487172. (48 citations; Daniel R. Mishell, Jr, MD, Outstanding Article Award)
8. Raymond EG, Weaver MA, Trussell J, **Reeves MF**. Estimating Contraceptive Effectiveness: The Case of Spermicides. *Contraception*. 87(2): 134-7, 2013 February. PMID 22840279. (6 citations)
9. Rodriguez MI, **Reeves MF**, Caughey AB. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis. *BJOG*. 119(9): 1067-73, 2012 August. PMID 22676150. (37 citations)
10. Hohmann HL, **Reeves MF**, Chen BA, Perriera LK, Hayes JA, Creinin MD. Immediate versus Delayed Insertion of the Levonorgestrel-Releasing Intrauterine Device Following Dilatation and Evacuation: A Randomized Controlled Trial. *Contraception*. 85(3): 240-5, 2012 March. PMID 22067762. (34 citations)
11. Behringer T, **Reeves MF**, Rossiter B, Chen BA, Schwarz EB. Duration of Use of a Levonorgestrel IUD amongst Nulliparous and Adolescent women. *Contraception*. 84(5): e5-10, 2011 November. PMID 22018136. (46 citations)

12. Hayes JA, Achilles SA, Creinin MD, **Reeves MF**. Outcomes of Medical Abortion through 63 Days in Women with Twin Gestations. *Contraception*. 84(5): 505-7, 2011 November. PMID 22018125. (8 citations)
13. Chen BA, **Reeves MF**, Creinin MD, Schwarz EB. Postplacental or Delayed Levonorgestrel Intrauterine Device Insertion and Breastfeeding Duration. *Contraception*. 84(5): 499-504, 2011 November. PMID 22018124. (52 citations)
14. Bednarek PH, Creinin MD, **Reeves MF**, Cwiak CA, Espey E, Jensen JT. Immediate Versus Delayed Intrauterine Device Insertion Following Uterine Aspiration between 5 and 12 Weeks Gestation: A Randomized Controlled Trial. *New England Journal of Medicine*. 364(23): 2212-21, 2011 June 9. PMID 21651392. [<http://dx.doi.org/10.1056/NEJMoa1011600>] (159 citations)
15. Kennedy MR, Meyn LA, **Reeves MF**, Wiesenfeld HC. Universal Prenatal HIV Screening: Are We There Yet? *International Journal of STD & AIDS*. 22(4): 194-8, 2011 April. PMID 21515750
16. Chen BA, **Reeves MF**, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or Delayed Insertion of the Levonorgestrel Intrauterine Device after Vaginal Delivery: A Randomized Controlled Trial. *Obstetrics and Gynecology*. 116(5): 1079-87, 2010 November. PMID 20966692. (149 citations; 2010 Roy M. Pitkin Award recipient)
17. **Reeves MF**, Goldstein RB, Jones KD. Communication of Adenomyosis with the Endometrial Cavity: Visualization with Saline-Infusion Sonohysterography. *Ultrasound in Obstetrics and Gynecology*. 36(1): 115-9, 2010 July. PMID 20069662. (13 citations)
18. Lohr PA, **Reeves MF**, Creinin MD. A Comparison of Transabdominal and Transvaginal Ultrasonography for the Determination of Gestational Age and Clinical Outcomes in Women Undergoing Early Medical Abortion. *Contraception*. 81(3): 240-4, 2010 March. PMID 20159181. (28 citations)
19. Perriera L, **Reeves MF**, Chen BA, Hohmann H, Hayes J, Creinin MD. The Feasibility of Telephone Follow-up after Medical Abortion. *Contraception*. 81(2): 143-9, 2010 February. PMID 20103453. (81 citations; *Contraception* Outstanding Article Award recipient)
20. **Reeves MF**, Fox MC, Lohr PA, Creinin MD. Endometrial Thickness Following Medical Abortion Is Not Predictive of Subsequent Surgical Intervention. *Ultrasound in Obstetrics and Gynecology*. 34(1): 104-9, 2009 July. PMID 19517421. (55 citations)
21. Drey EA, **Reeves MF**, Ogawa DD, Sokoloff A, Darney PD, Steinauer JE. Insertion of Intrauterine Contraception Immediately Following First- and Second-Trimester Abortion. *Contraception*. 79(5): 397-402, 2009 May. PMID 19341854. (46 citations)
22. Borrero S, Schwarz E, **Reeves MF**, Bost JE, Creinin MD, Ibrahim S. Does Vasectomy Explain The Difference in Tubal Sterilization Rates between Black and White Women? *Fertility & Sterility*. 91(5): 1642-5, 2009 May. PMID 18394618; PMC 2697852. (16 citations)
23. **Reeves MF**, Lohr PA, Hayes JA, Harwood BJ, Creinin MD. Doxycycline Serum Levels at the Time of Dilatation and Evacuation with Two Dosing Regimens. *Contraception*. 79(2): 129-33, 2009 February. PMID 19135570. (14 citations)
24. **Reeves MF**, Kudva A, Creinin MD. Medical Abortion Outcomes after a Second Dose of Misoprostol for Persistent Gestational Sac. *Contraception*. 78(4): 332-5, 2008 October. PMID 18847584. (22 citations)
25. Schwarz EB, Smith R, Steinauer J, **Reeves MF**, Caughey AB. Measuring the Effects of Unintended Pregnancy on Women's Quality of Life. *Contraception*. 78(3): 204-10, 2008 September. PMID 18692610; PMC 2580059. (61 citations)
26. O'Neill E, **Reeves MF**, Creinin MD. Baseline Colposcopic Findings in Women Entering Studies on Female Vaginal Products. *Contraception*. 78(2): 162-6, 2008 August. PMID 18672119. (11 citations)

27. Goodman S, Hendlish SK, **Reeves MF**, Foster-Rosales A. Impact of Immediate Post-Abortal Insertion of Intrauterine Contraception on Repeat Abortion. *Contraception*. 78(2): 143-8, 2008 August. PMID 18672116. (160 citations)
28. Goodman S, Hendlish SK, Benedict C, **Reeves MF**, Pera-Floyd M, Foster-Rosales A. Increasing Intrauterine Contraception Use By Reducing Barriers To Post-Abortal and Interval Insertion. *Contraception*. 78(2): 136-42, 2008 August. PMID 18672115. (79 citations)
29. Borrero S, **Reeves MF**, Schwarz E, Bost JE, Creinin MD, Ibrahim SA. Race, Insurance Status, and Desire for Tubal Sterilization Reversal. *Fertility & Sterility*. 90(2): 272-7, 2008 August. PMID 17880952; PMC 2732356. (30 citations)
30. Kazi S, **Reeves MF**, Creinin MD. The Prevalence of Domestic Violence in Women who Volunteer for Abortion and Contraceptive Research Studies. *Contraception*. 78(1): 79-83, 2008 July. PMID 18555822. (13 citations)
31. Chen BA, **Reeves MF**, Creinin MD, Gilles JM, Barnhart K, Westhoff C, Zhang JM. Misoprostol for Treatment of Early Pregnancy Failure in Women with Prior Uterine Surgery. *American Journal of Obstetrics & Gynecology*. 198(6): 626.e1-5, 2008 June. PMID 18279821; PMC 2519868. (30 citations)
32. **Reeves MF**, Lohr PA, Harwood BJ, Creinin MD. Ultrasonographic Endometrial Thickness after Medical and Surgical Management of Early Pregnancy Failure. *Obstetrics & Gynecology*. 111(1): 106-12, 2008 January. PMID 18165398. (40 citations)
33. Lohr PA, **Reeves MF**, Hayes JA, Harwood BJ, Creinin MD. Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion: A Pilot Study. *Contraception*. 76(3): 215-20, 2007 September. PMID 17707719. (19 citations)
34. **Reeves MF**, Smith KJ, Creinin MD. The Contraceptive Effectiveness of Immediate Compared with Delayed Insertion of Intra-Uterine Devices after Abortion: A Decision Analysis. *Obstetrics & Gynecology*. 109(6): 1286-94, 2007 June. PMID 17540799. [<http://dx.doi.org/10.1097/01.AOG.0000265336.14160.cc>] (54 citations)
35. Hogge WA, Prosen TL, Lanasa MC, Huber HA, **Reeves MF**. Recurrent Pregnancy Loss and Skewed X-inactivation: Is There an Association? *American Journal of Obstetrics & Gynecology*. 196 (4): 384.e1-8, 2007 April. PMID 17403428. (29 citations)
36. Schwarz EB, **Reeves MF**, Gerbert B, Gonzales R. Knowledge of and Perceived Access to Emergency Contraception at Two Urgent Care Clinics in California. *Contraception*. 75(3): 209-13, 2007 March. PMID 17303491. (31 citations)
37. Borrero S, Schwarz EB, **Reeves MF**, Bost JE, Creinin MD, Ibrahim SA. Race, Insurance Status, and Tubal Sterilization. *Obstetrics & Gynecology*. 109(1): 94-100, 2007 January. PMID 17197593. (56 citations)
38. Schreiber CA, Creinin MD, **Reeves MF**, Harwood BJ. Mifepristone and Misoprostol for the Treatment of Early Pregnancy Failure: A Pilot Clinical Trial. *Contraception*. 74(6): 458-62, 2006 December. PMID 17157102. (31 citations)
39. Schreiber CA, Harwood BJ, Switzer GE, Creinin MD, **Reeves MF**, Ness RB. Training and Attitudes about Contraceptive Management across Primary Care Specialties: A Survey of Graduating Residents. *Contraception*. 73(6): 618-22, 2006 June. PMID 16730495. (57 citations)
40. Tanaka F, **Reeves M**, Ito Y, Matsumoto M, Lei M, Miwa S, Inukai A, Yamamoto M, Doyu M, Yoshida M, Hashizume Y, Teao S, Mitsuma T, Sobue G. Tissue-Specific Somatic Mosaicism in Spinal and Bulbar Muscular Atrophy Is Dependent on CAG-Repeat Length and Androgen Receptor-Gene Expression Level. *American Journal of Human Genetics*. 65: 966-73, 1999 Oct. PMID 10486315; PM1288267. (67 citations)

41. Grinspan J, Marchionni M, **Reeves M**, Coulaloglou M, Scherer S. Axonal Interactions Regulate Schwann Cell Apoptosis in Developing Peripheral Nerve: Neuregulin Receptors and the Role of Neuregulins. *Journal of Neuroscience*. 16(19): 6107-18, 1996 Oct 1. (330 citations)
42. Grinspan JB, **Reeves MF**, Coulaloglou MJ, Nathanson D, Pleasure D. Re-entry into the Cell Cycle Is Required for bFGF-induced Oligodendroglial Dedifferentiation and Survival. *Journal of Neuroscience Research*. 46(4): 456-64, 1996 Nov 15. PMID 8950705. (69 citations)

#### INVITED PUBLICATIONS

1. Ruggiero S, Brandi K, Mark A, Paul M, **Reeves MF**, Schalit O, Blanchard K, Key K, Chandrasekaran S. Access to later abortion in the United States during COVID-19: Challenges and recommendations from providers, advocates, and researchers. *Sexual and Reproductive Health Matters*. 28(1): 1-3, 2020 June. PMID: 32460663 [<https://doi.org/10.1080/26410397.2020.1774185>]
2. Mark A, Blumenthal PD, Foster AM, Jones RK, Nichols MD, Prager SW, **Reeves MF**, Ragsdale KH. Fighting for access: research at the National Abortion Federation's 43rd annual meeting. *Contraception*. 99(5): 313-4, 2019 May.
3. Mark A, Foster AM, Grossman D, Prager SW, **Reeves MF**, Villarreal CV, Winikoff B. Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee. *Contraception*. 99(5): 265–266, 2019 May. (5 citations) [<https://doi.org/10.1016/j.contraception.2019.02.008>].
4. **Reeves MF**, Mark A, Jones RK, Blumenthal PD, Nichols MD, Saporta VA. Abortion Research at the 2018 National Abortion Federation Annual Meeting. *Contraception*. 97(5):458-9, 2018 May. PMID: 29747843.
5. Mark A, **Reeves MF**, Blumenthal PD, Jones RK, Nichols MD, Saporta VA. Putting research into practice at the 2017 National Abortion Federation Annual Meeting. *Contraception*. 95(5): 512-4, 2017 May. PMID 28315302.
6. Conti JA, Brant AR, Shumaker HD, **Reeves MF**. Update on abortion policy. *Current Opinion in Obstetrics & Gynecology*. 28(6): 517-521, 2016 Dec. PMID 27805969. (11 citations)
7. **Reeves MF**, Blumenthal PD, Jones RK, Nichols MD, Shumaker H, Saporta VA. Innovative research at the 2016 National Abortion Federation Annual Meeting: putting research into practice. *Contraception*. 93(5): 375-7, 2016 May. PMID 27107178.
8. **Reeves MF**, Blumenthal PD, Jones RK, Nichols MD, Saporta VA. New research at the 2015 National Abortion Federation Annual Meeting: putting research into practice. *Contraception*. 91(5): 359, 2015 May. PMID 25926081.
9. **Reeves MF**, Blumenthal PD, Jones RK, Nichols MD, Saporta VA. New Research at the 2014 National Abortion Federation Annual Meeting: Continuously Improving Abortion Care. *Contraception*. 89(5): 339-40, 2014 May. PMID 24661559.
10. **Reeves MF**, Schwartz JL. Female-controlled barrier contraception. In: Shoupe D, editor. *Gynecology in Practice: Contraception*. London: Wiley-Blackwell, 2011.
11. Achilles S, **Reeves MF**, Society of Family Planning. Prevention of Infection at Elective Abortion: SFP guideline 20102. *Contraception*. 83(4): 295-309, 2011 April. PMID 21397086. (84 citations)
12. Goldstein SR, **Reeves MF**. Assessing Pregnancy Status and Gestational Age. In: Paul M, Lichtenberg S, Borgatta L, Grimes D, Stubblefield P, Creinin M, editors. *Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care*. London: Wiley-Blackwell, 2009.
13. Perriera L, **Reeves MF**. Ultrasound Criteria for Diagnosis of Early Pregnancy Failure and Ectopic Pregnancy. [Review] *Seminars in Reproductive Medicine*. 26(5): 373-82, 2008. PMID 18825605. (28 citations)



14. Deutchman M, **Reeves MF**, Fjerstad M, Andrews M. Ultrasound in Abortion Care. [CD-ROM] Planned Parenthood Federation of America & National Abortion Federation, joint project. 2007.
15. Tran TL, **Reeves MF**, Cwiak C, et al. *A Pocket Guide to Managing Contraception: Vietnamese Edition*. Ho Chi Minh City, Vietnam: University of Medicine & Pharmacy, 2006.
16. **Reeves MF**, Creinin MD. Mortality in Perspective: Mifepristone-Misoprostol Medical Abortion [Commentary]. *Advanced Studies in Medicine*. 6(10): 428-30, 2006 Nov/Dec.
17. **Reeves MF**, Creinin MD. Post-procedural Upper Genital Tract Infections. In: Sweet RL, Wiesenfeld HC, editors. *Pelvic Inflammatory Disease*. London: Taylor & Francis; 2006.

#### ABSTRACTS

1. Brant A, Ye P, Scott R, **Reeves M**, Lotke P. Gabapentin for Pain Control During Dilation and Evacuation: A Double-Blind Randomized Controlled Trial. *Contraception*. 101(5): 355, 2020 May [accepted for oral presentation, National Abortion Federation Annual Meeting, 30 March 2020, Washington, DC; <https://doi.org/10.1016/j.contraception.2020.03.011>]
2. **Reeves MF**, Rubin SL, Goldfarb CN. Intrafetal injection of lidocaine to induce fetal demise. *Contraception*. 99(5): 319, 2019 May. [oral presentation, National Abortion Federation Annual Meeting, 6 May 2019, Chicago, IL].
3. Horvath-Cosper D, Lotke P, Ye P, **Reeves M**. A randomized controlled trial of three prophylactic antibiotic regimens for first-trimester surgical abortion. *Contraception*. 98(4): 343-4, 2018 October. [poster presentation, 2018 North American Forum on Family Planning, New Orleans]
4. **Reeves MF**, Rubin SL. Intrafetal injection of lidocaine to induce fetal demise. *International Journal of Gynecology & Obstetrics*. 143(S3): 382-3. [oral presentation, XXII FIGO World Congress, 16 October 2018, Rio de Janeiro, Brazil].
5. **Reeves MF**, Rubin SL. Intrafetal injection of lidocaine to induce fetal demise. 13<sup>th</sup> FIAPAC Conference, Nantes, France. September 2018 [poster presentation].
6. Kohn J, Della Badia L, **Reeves M**, McDonald-Mosley R. Communicating About Post-Abortion Pregnancy Tissue Management: A Structured Assessment of Patient Preferences. NAF Annual Meeting, Seattle, WA. April 2018 [poster presentation].
7. Casey F, Wegelin J **Reeves M**. Twenty-Four Hour Mifepristone Combined with Vaginal Versus Buccal Misoprostol Prior to D&E. *Obstetrics & Gynecology*. 131: 76S, 2018 May. [poster presentation, 2018 Annual Clinical Meeting, American College of Obstetrics & Gynecology, Austin, TX]
8. Shakir J, Ye P, Perritt J, Lotke P, **Reeves M**. A factorial-design randomized controlled trial comparing misoprostol alone to dilapan with misoprostol and comparing buccal to vaginal misoprostol for same-day cervical preparation prior to dilation & evacuation (MiDi Study). *Contraception*. 96(4): 271, 2017 October. [poster presentation, 2017 North American Forum on Family Planning, Atlanta]
9. Schwarz EB, Lewis CA, Borrero S, **Reeves M**. Pregnancy after tubal sterilization in the US, updated estimates. *Contraception*. 96(4): 268, 2017 October. [oral presentation, 2017 North American Forum on Family Planning, Atlanta]
10. **Reeves MF**, Hathaway MJ, Canela Oleaga JM, Katz BH, Tal MG. A randomized trial of Veracept, a novel nitinol low-dose copper intrauterine contraceptive, compared to a copper T380S intrauterine contraceptive. [Oral presentation, 14th ESC Congress & 2nd Global Conference, European Society of Contraception and Reproductive Health, Basel, Switzerland, May 2016]
11. **Reeves MF**, Hathaway MJ, Canela Oleaga JM, Katz BH, Tal MG. A Randomized Single-Blinded Trial of VeraCept, a Novel Nitinol Low-Dose Copper Intrauterine Contraceptive Compared to a Copper T380S Intrauterine Contraceptive. *Obstetrics & Gynecology*. 125S1:5S, 2015 May. [oral presentation, 2015 Annual Clinical Meeting, American College of Obstetrics & Gynecology, San Francisco]
12. Tal RM, **Reeves MF**, Hathaway MJ, Canela Oleaga JM, Katz BH, Tal MG. A Proposed Classification for Intrauterine Device Position. A Proposed Classification for Intrauterine Device Position. *Obstetrics & Gynecology*. 125S1:74S, 2015 May. [poster, 2015 Annual Clinical Meeting, American College of Obstetrics & Gynecology, San Francisco]
13. Shakir JM, Burke AE, **Reeves MF**. Predictors for Current IUD Use Compared to Female Sterilization among U.S. Women. *Obstetrics & Gynecology*. 125S1:69S, 2015 May. [poster, 2015 Annual Clinical Meeting, American College of Obstetrics & Gynecology, San Francisco]

14. Casey F, Moreno-Ruiz N, Dinneen J, Perritt J, Hathaway M, **Reeves M**. A Randomized Double-blinded Comparison of Same-Day Mifepristone and Misoprostol with Misoprostol only for Cervical Preparation in Second-Trimester Surgical Abortion. *Contraception*. 90(3): 293, 2014 September. [oral presentation, 2014 North American Forum on Family Planning, Miami]
15. **Reeves M**, Zhao Q, Peipert J, Secura G. Risk of Subsequent Pregnancy Based on Contraceptive Method Choice at Enrolment: An Intention-To-Treat Analysis of the CHOICE Project Data. *Contraception*. 90(3): 330, 2014 September. [poster, 2014 North American Forum on Family Planning, Miami]
16. **Reeves M**, Katz B, Canela J, Hathaway M, Tal M. Initial Evaluation of a Novel Nitinol, Low-dose-copper Intrauterine Contraceptive. *Contraception*. 90(3): 315, 2014 September. [poster, 2014 North American Forum on Family Planning, Miami]
17. **Reeves MF**, Loi TT, Hoang TD, Thang HV, Hien LV, Creinin MD. A Randomized Double-Blinded Comparison of Single-Dose Pre-Operative Doxycycline to 5-Day Post-Operative Doxycycline for the Prevention of Infection Following First-Trimester Uterine Evacuation. *International Journal of Gynecology & Obstetrics*. 119(S3): S461. [oral presentation, FIGO World Congress 2012, Rome]
18. **Reeves MF**, Cwiak C, Espey E, Creinin M, Nichols M, Bednarek P. The utility of sonographic assessment of intrauterine device placement following immediate versus delayed insertion following uterine aspiration. *Contraception*. 82(2): 184, 2010 August. [oral presentation, Reproductive Health 2010]
19. Creinin M, Bednarek P, **Reeves M**, Cwiak C, Espey E. Resumption of sexual activity after first-trimester suction aspiration. *Contraception*. 82(2): 188, 2010 August. [oral presentation, Reproductive Health 2010]
20. Chen B, **Reeves M**, Hohmann H, Creinin M. Comparing outcomes following immediate or delayed levonorgestrel-IUD insertion after dilation and curettage, dilation and evacuation, and vaginal delivery. *Contraception*. 82(2): 192, 2010 August. [poster, Reproductive Health 2010]
21. Behringer T, **Reeves M**, Rossiter B, Chen B, Schwarz E. The effect of parity on reasons for removal of a Levonorgestrel IUS. *Contraception*. 82(2): 200, 2010 August. [poster, Reproductive Health 2010]
22. Kottke M, Bednarek P, Creinin M, **Reeves M**, Espey E, Goedken M, Haddad L, Lathrop E, Cwiak C. Characteristics of women who fail to return for delayed IUD insertion for post-abortion contraception. *Contraception*. 82(2): 203, 2010 August. [poster, Reproductive Health 2010]
23. Creinin M, Bednarek P, **Reeves M**, Cwiak C, Espey E. Pain following post-aspiration IUD insertion. *Contraception*. 82(2): 189-90, 2010 August. [poster, Reproductive Health 2010]
24. Bednarek P, Creinin M, **Reeves M**, Cwiak C, Espey E, Mayo J, Jensen J. Pain with IUD insertion following prophylactic ibuprofen: A randomized trial. *Contraception*. 82(2): 194-5, 2010 August. [poster, Reproductive Health 2010]
25. Courtney-Brooks M, **Reeves MF**. Thickened endometrial lining in menstruating women: Is there an association with pathology? [poster, 2010 Annual Clinical Meeting, American College of Obstetrics & Gynecology, San Francisco]
26. Bednarek PH, Botha RL, Creinin MD, **Reeves MF**, Cwiak CA, Espey E, Jensen JT. The effect of immediate IUD insertion on bleeding patterns following first-trimester suction aspiration. [oral presentation, American Society for Reproductive Medicine 2009 annual conference]
27. **Reeves MF**, Borrero S, Schwarz EB, Behringer T, Noguchi LM, Robert MS, Creinin MD. Pregnancy after tubal sterilization in the United States. *International Journal of Gynecology & Obstetrics*. 107(S2): S319. [oral presentation, FIGO World Congress 2009, Cape Town]
28. Bednarek PH, Creinin MD, **Reeves MF**, Cwiak CA, Espey E, Jensen JT. Immediate intrauterine device insertion following suction aspiration between 5-12 weeks gestation is safe and does not significantly increase expulsion. *International Journal of Gynecology & Obstetrics*. 107(S2): S122-S3, 2009 Nov. [oral presentation, FIGO World Congress 2009, Cape Town]
29. Hohmann H, **Reeves MF**, Chen BA, Perriera L, Hayes JA, Creinin MD. Immediate versus Delayed Insertion of the Levonorgestrel-Releasing Intrauterine Device Following Dilation and Evacuation: A Randomized Controlled Trial. *Contraception*. 80(2): 209, 2009 August. [poster, Reproductive Health 2009]
30. Chen BA, Hayes JL, Hohmann HL, Perriera LK, **Reeves MF**, Creinin MD. A randomized trial of postplacental compared to delayed insertion of the levonorgestrel-releasing intrauterine device after vaginal delivery. *Contraception*. 80(2): 205, 2009 August. [poster, Reproductive Health 2009]

31. Chen BA, Creinin MD, **Reeves MF**, Schwarz EB. Breastfeeding continuation among women using the levonorgestrel-releasing intrauterine device after vaginal delivery. *Contraception*. 80(2): 204-5, 2009 August. [poster, Reproductive Health 2009]
32. Chen BA, Hayes JL, Hohmann HL, **Reeves MF**, Creinin MD. Trends in tubal sterilization and intrauterine device uptake at an urban academic medical center. *Contraception*. 80(2): 205-6, 2009 August. [poster, Reproductive Health 2009]
33. Chen BA, Hayes JL, Hohmann H, **Reeves MF**, Creinin MD. Outcomes of Essure hysteroscopic sterilization in an urban academic medical center. *Contraception*. 80(2): 205, 2009 August. [poster, Reproductive Health 2009]
34. Perriera L, Chen BA, Hayes JL, Hohmann H, **Reeves MF**, Creinin MD. The Feasibility of Telephone Follow-up after Medical Abortion. *Contraception*. 80(2): 197, 2009 August. [oral presentation, Reproductive Health 2009]
35. Cwiak CA, Bednarek PH, **Reeves MF**, Espey E, Creinin MD. Uterine infection following immediate or delayed post-aspiration intrauterine device insertion. *Contraception*. 80(2): 210, 2009 August. [poster, Reproductive Health 2009]
36. Bednarek PH, Creinin MD, **Reeves MF**, Cwiak CA, Espey E, Jensen JT. Immediate intrauterine device insertion following suction aspiration between 5-12 weeks gestation increases rates of insertion and utilization compared to scheduled delayed insertion. *Contraception*. 80(2): 203, 2009 August. [poster, Reproductive Health 2009]
37. Creinin MD, Bednarek PH, **Reeves MF**, Cwiak CA, Espey E. Incomplete and failed abortion following immediate or delayed post-aspiration IUD insertion. *Contraception*. 80(2): 203, 2009 August. [poster, Reproductive Health 2009]
38. Samuel A, **Reeves MF**, Emery SP. Cesarean scar ectopic pregnancies: a case series. [poster, 2009 Annual Clinical Meeting, American College of Obstetrics and Gynecology, Chicago]
39. Hayes JL, Achilles S, **Reeves MF**, Creinin MD. Outcome of medical abortion through 63 days in women with twin gestation. *Contraception*. 78(2): 168-9, 2008 August. [Best oral presentation award winner, Reproductive Health 2008]
40. **Reeves MF**, Fox MC, Creinin MD. Ability of Endometrial Thickness Following Medical Abortion to Predict Subsequent Surgical Intervention. *Contraception*. 76(2): 162, 2007 August. [poster, Reproductive Health 2007]
41. **Reeves MF**, Lohr PA, Hayes JA, Harwood BJ, Creinin MD. Serum Levels of Doxycycline at the Time of Dilatation and Evacuation with Two Dosing Regimens. *Contraception*. 76(2): 162, 2007 August. [poster, Reproductive Health 2007]
42. Kudva A, **Reeves MF**, Creinin MD. Medical abortion outcomes after a second-dose of misoprostol: Is the presence of cardiac motion on follow-up ultrasonography predictive of failure? *Contraception*. 76(2): 162-3, 2007 August. [poster, Reproductive Health 2007]
43. Lohr PA, **Reeves MF**, Creinin MD. Eliciting Women's Preferences in Medical Abortion Treatment Using Willingness to Pay. *Contraception*. 76(2): 164, 2007 August. [poster, Reproductive Health 2007]
44. Lohr PA, **Reeves MF**, Creinin MD. Accuracy of Abdominal Ultrasonography in Determining Gestational Age and Outcomes in Early Medical Abortion. *Contraception*. 76(2): 162, 2007 August. [poster, Reproductive Health 2007]
45. Chen BA, **Reeves MF**, Giles JM, Zhang J, Creinin MD. Misoprostol for Treatment of Early Pregnancy Failure in Women with Prior Uterine Surgery. *Contraception*. 76(2): 163, 2007 August. [poster, Reproductive Health 2007]
46. Chen BA, **Reeves MF**, Creinin MD. Outcome of Medical Abortion through 63 Days in Women with Prior Cesarean Section. *Contraception*. 76(2): 163, 2007 August. [poster, Reproductive Health 2007]
47. Hohmann H, **Reeves MF**, Hayes JA, Lohr PA, Chen BA, Creinin MD. Predictors of dilation and curettage in medical abortion through 63 days. *Contraception*. 76(2): 163-4, 2007 August. [poster, Reproductive Health 2007]
48. Hohmann H, **Reeves MF**, Hayes JA, Lohr PA, Chen BA, Creinin MD. Predictors of pain and bleeding in medical abortion. *Contraception*. 76(2): 163, 2007 August. [poster, Reproductive Health 2007]
49. Kazi S, **Reeves MF**, Creinin MD. The Prevalence of Domestic Violence in Women Who Volunteer for Gynecologic Research Studies. *Contraception*. 76(2): 168-9, 2007 August. [poster, Reproductive Health 2007]
50. Borrero S, Schwarz EB, **Reeves MF**, Bost JE, Creinin MD. Does vasectomy explain the difference in tubal sterilization rates between black and white women? *Contraception*. 76(2): 173, 2007 August. [poster, Reproductive Health 2007]
51. Ogawa D, Sokoloff A, **Reeves MF**, Steinauer J, Darney PD, Drey EA. Post-abortion insertion of intrauterine contraception in the first and second trimesters. *Obstetrics & Gynecology*. 109 (4): S61, 2007 May. [poster, 2007 Annual Clinical Meeting, American College of Obstetrics & Gynecology]

52. Goodman S, Benedict C, **Reeves MF**, Pera-Floyd M, Hendlish SK, Foster-Rosales A. Minimizing Barriers to IUD Use: Do Interventions that Improve Access Have an Impact on Repeat Abortion. 2007 April. [poster, 2007 Annual Meeting, National Abortion Federation]
53. **Reeves MF**, Lohr PA, Harwood BJ, Creinin MD. Sonographic Findings after Misoprostol or Vacuum Aspiration for Early Pregnancy Failure. *Contraception*. 74(2): 182, 2006 August. [oral presentation, Reproductive Health 2006]
54. **Reeves MF**, Schreiber CA, Harwood BJ, Creinin MD. Acceptability of Medical Uterine Evacuation among Women with Normal and Abnormal First-Trimester Pregnancies. *Contraception*. 74(2): 184-5, 2006 August. [poster, Reproductive Health 2006]
55. Lohr PA, **Reeves MF**, Hayes JL, Harwood BJ, Creinin MD. Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation. *Contraception*. 74(2): 181, 2006 August. [oral presentation, Reproductive Health 2006]
56. Goodman S, Benedict C, **Reeves MF**, Pera-Floyd M, De La Cruz M, Foster-Rosales A. Minimizing Barriers to IUD Use: the Impact of Post-Abortal IUDs, Simplified Screening Criteria, and Staff Re-Introduction. *Contraception*. 74(2): 180, 2006 August. [oral presentation, Reproductive Health 2006]
57. Borrero S, Creinin M, Bost J, McNeil M, Schwarz E, **Reeves M**, Ibrahim S. Race, Insurance Status, and Tubal Sterilization. *Contraception*. 74(2): 193, 2006 August. [poster, Reproductive Health 2006]
58. **Reeves MF**, Smith KJ, Creinin MD. The Cost-Effectiveness of Antibiotic Use at Surgical Abortion by Age and Desire for Future Childbearing. 2005 October. [poster, Society for Medical Decision Making]
59. **Reeves MF**, Smith KJ, Creinin MD. Decision Analysis of the Effectiveness of Contraception by Immediate Versus Delayed Insertion of Intra-Uterine Devices after Abortion. 2005 October. [poster, Society for Medical Decision Making]
60. **Reeves MF**, Smith KJ, Creinin MD. The Cost-Effectiveness of Antibiotic Use at Surgical Abortion: Comparing Prophylactic to Treatment Regimens. *Contraception*. 72(3): 242-243, 2005 September. [poster, Reproductive Health 2005]
61. **Reeves MF**, Smith KJ, Creinin MD. Decision Analysis of Immediate Versus Delayed Insertion of Intra-Uterine Devices after Abortion to Prevent Pregnancy. *Contraception*. 72(3): 237, 2005 September. [poster, Reproductive Health 2005]
62. Schreiber CA, Creinin MD, Harwood BJ, **Reeves MF**. Mifepristone and Misoprostol for the Treatment of Early Pregnancy Failure: A Pilot Clinical Trial. *Contraception*. 72(3): 239, 2005 September. [poster, Reproductive Health 2005]
63. Schreiber CA, Harwood BJ, Switzer G, Ness R, **Reeves MF**, Creinin, MD. Training and Attitudes about Contraceptive Management across Primary Care Specialties: A Survey of Graduating Residents. *Contraception*. 72(3): 243, 2005 September. [poster, Reproductive Health 2005]
64. **Reeves MF**, Goldstein RB. Adenomyotic lesion communicating with the endometrial cavity as seen on saline-infusion sonohysterography. 2004 March. [poster, First International Scientific Meeting, International Society of Ultrasound in Obstetrics and Gynecology, Singapore]
65. Grinspan J, **Reeves M**, Scherer S. Apoptosis in the rat sciatic nerve during development and following axotomy. *Frontiers of Myelinating Cell Biology*. August 19, 1995.

#### OTHER PUBLICATIONS

1. **Reeves MF**. Ellipsoid volume formula [Letter]. *Contraception*. 76(3): 334, 2007 September.
2. **Reeves MF**. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 µg of ethinyl estradiol and 3 mg of drospirenone [Letter re: intention-to-treat analysis]. *Contraception*. 75(6): 474, 2007 June.
3. **Reeves MF**. Prediction of methotrexate treatment failure in ectopic pregnancy [Letter]. *Journal of Ultrasound in Medicine*. 24(1): 1167-1168, 2005 August.
4. **Reeves MF**, Harwood BA, Creinin MD. The challenges of analyzing cost-effectiveness with a computer model [Letter]. *Fertility & Sterility*. 84(2):543, 2005 August.
5. Noguchi LM, **Reeves MF**. Simple interventions can save newborn lives, A Review of "Evidence-based, cost-effective interventions: How many newborn babies can we save?" [*Lancet*, 365(9463): 977-88]. [Article Review] *Journal of Midwifery and Women's Health*. 50(4): 351-2, 2005 July.



---

**SEMINARS AND INVITED LECTURESHIPS**


---

1. Complex Family Planning: Opportunities and Challenges. Invited Speaker, Grand Rounds. Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, November 25, 2020.
2. Abortion Provider Panel. Invited Speaker, GW Medical Students for Choice. November 3, 2020.
3. A Patient-Centered Approach to Understanding Barriers to Later Abortion Access. Invited Speaker, Webinar, Funder for Reproductive Equity. June 18, 2020.
4. Starting Your Own Practice. Invited Speaker, Webinar, Medical Students for Choice. May 20, 2020.
5. Provider Experiences Using Shortened Later Abortion Procedures. Invited speaker, Webinar. Later Abortion Network. April 29, 2020.
6. Protecting Later Abortion Access During COVID-19 Pandemic. Invited speaker, Webinar. Later Abortion Network. March 31, 2020.
7. Post-Graduate Seminar: Ultrasound in Abortion Care. Invited Course chair, NAF Annual Meeting, Chicago, IL. May 5, 2019.
8. Intrauterine Ectopic Pregnancies: Cornual, Cervical, and Cesarean Scar. Invited Speaker, Grand Rounds. Department of Obstetrics and Gynecology, The George Washington University, March 27, 2019.
9. Advanced Applications of Ultrasound in Abortion Care. Invited speaker, PPFA Medical Director's Committee 15th Annual Update on Reproductive Health and Medical Leadership, Dallas, Texas. March 1, 2019.
10. Second Trimester Abortion. Invited Panelist, 13<sup>th</sup> FIAPAC Conference, Nantes, France. September 14, 2018.
11. Hemorrhage Management: Evidence and Practices for Prophylaxis and Treatment. Invited speaker, NAF Annual Meeting, Seattle, WA. April 24, 2018.
12. Post-Graduate Seminar: Reducing pain in abortion care. Course chair, NAF Annual Meeting, Seattle, WA. April 22, 2018.
13. Instruments for D&E. Invited Speaker, Basics of Second-Trimester Abortion Workshop, NAF Annual Meeting, Seattle, WA. April 21, 2018.
14. Ultrasound After 14 Weeks. Invited Speaker, Basics of Second-Trimester Abortion Workshop, NAF Annual Meeting, Seattle, WA. April 21, 2018.
15. The impact of TRAP laws on physicians and the care they give. Invited Speaker, with Dr. Kirtly Parker Jones and Judith Daar, Symposium: Medical and Legal Aspects of Targeted Regulation of Abortion Providers (TRAP) Laws. University of Utah S.J. Quinney College of Law, Salt Lake City, UT. December 1, 2017
16. Advocacy for reproductive health. Grand Rounds invited Speaker, with Drs. Willie Parker & Anne Davis, University of Utah Department of Obstetrics and Gynecology, Salt Lake City, UT. November 30, 2017
17. Casos difíciles. NAF Congreso Regional Latinoamericano, Lima, Peru. 11 Noviembre 2017.
18. Ecografía en la atención del aborto. NAF Congreso Regional Latinoamericano, Lima, Peru. 11 Noviembre 2017.
19. Difficult cases. Invited panelist, NAF Regional Meeting, Halifax, Nova Scotia. October 22, 2017.
20. Ultrasound in abortion care. Invited speaker, NAF Regional Meeting, Halifax, Nova Scotia. October 21, 2017.
21. What about pregnancies that aren't seen on ultrasound? Invited speaker; 19th Annual Mifepristone Medical Abortion Meeting, Gynuity Health Projects, New York, NY. June 6, 2017.
22. Prior Cesarean as a risk factor for complication at D&E. Invited Speaker, NAF Annual Meeting, Montreal, QC. April 22, 2017.
23. Medical Abortion with Mifepristone and Misoprostol. Invited Speaker, DKT Country Director's Meeting, Dubrovnik, Croatia. April 13, 2017.
24. Contraceptive Efficacy: Understanding the Reality for Clinicians. Invited Speaker, Obstetrics and Gynecology Grand Rounds, MedStar Washington Hospital Center, Washington, DC. March 9, 2017.
25. Ultrasound in Abortion Care. Invited speaker, Clinicians for Choice, webinar. February 28, 2017.
26. Ultrasound in Abortion Care. Invited speaker, Fellowship in Family Planning & Ryan Program, webinar. December 12, 2016.
27. Pregnancy of unknown location: diagnosis, sonographic assessment, and clinical management. Invited Speaker, North American Forum on Family Planning, Denver, CO. November 7, 2016.
28. Ultrasound in Abortion Care. Invited speaker, NAF Regional Meeting, Fort Lauderdale, FL. October 24, 2016.

## Curriculum Vitae

Matthew F. Reeves, MD, MPH

29. Overview of Contraception. Invited Speaker, Medical Students for Choice Regional Meeting, Lisbon, Portugal. October 15, 2016.
30. Free Communications. Invited Moderator, FIAPAC Congress 2016, Lisbon, Portugal. October 14, 2016.
31. Dilation and Evacuation Workshop. Invited Speaker, FIAPAC Congress 2016, Lisbon, Portugal. October 13, 2016.
32. Difficult cases. Invited panelist, NAF Regional Meeting, Calgary, Alberta. September 17, 2016.
33. First trimester abortion workshop. Invited speaker, NAF Regional Meeting, Calgary, Alberta. September 17, 2016.
34. Placenta accreta. Invited speaker, NAF Regional Meeting, Calgary, Alberta. September 17, 2016.
35. Aborto y ultrasonido: el gran debate. Profesor conferencista invitado, XXI Congreso, Colegio Mexicano de Especialistas de Ginecología y Obstetricia, Ciudad de México. June 23, 2016.
36. Post-graduate Course. Course organizer, NAF Annual Meeting, Austin, TX. April 17, 2016.
37. Pregnancy of Unknown Location and Very Early Abortion. Invited Speaker, NAF Annual Meeting, Austin, TX. April 17, 2016
38. Complications of Second Trimester Abortion. Invited Speaker, NAF Annual Meeting, Austin, TX. April 16, 2016
39. Diagnosis of Non-tubal Ectopic Pregnancies. Invited Speaker, North American Forum on Family Planning, Chicago, IL. November 16, 2015.
40. Introduction to Mifepristone. Invited speaker, NAF Regional Meeting, Montreal, Quebec. November 8, 2015.
41. Ultrasound in Abortion Care. Invited speaker, NAF Regional Meeting, Montreal, Quebec. November 8, 2015.
42. IUD Insertion at Time of Abortion. Invited speaker, NAF Regional Meeting, Montreal, Quebec. November 7, 2015.
43. Pregnancy of Unknown Location. Invited speaker, NAF Regional Meeting, Montreal, Quebec. November 7, 2015.
44. Measuring hCG before and after medical abortion. Invited speaker, Update on the Effectiveness and Availability of Semi-Quantitative Pregnancy Tests, Taaffe House, Los Altos, CA. October 29, 2015.
45. Ultrasound in Abortion Care. Invited speaker, NAF Regional Meeting, Albuquerque, NM. October 19, 2015.
46. Contraception after Abortion. Invited speaker, NAF Regional Meeting, Albuquerque, NM. October 18, 2015.
47. Hands-On Training in Manual Uterine Aspiration. Invited Trainer, FIGO World Congress, Vancouver, BC. October 7, 2015.
48. Introduction to Medical Abortion with Mifepristone and Misoprostol. Meeting Chair and Speaker, NAF Meeting, Vancouver, BC. October 3, 2015.
49. Introduction to Second-Trimester Surgical Abortion. NAF Annual Meeting, Baltimore, MD. April 18, 2015.
50. Building an Abortion Provider Network in the South. Co-convenor and moderator, Atlanta, GA. March 22, 2015
51. Public Health Student's for Choice meeting. Invited speaker, Baltimore, MD. March 25, 2015
52. Townhall meeting with Rep. Eleanor Holmes Norton. Invited speaker, Washington, DC. March 24, 2015
53. Ecografía en la atención del aborto. NAF Congreso Regional Latinoamericano, Bogotá, Colombia. 8 Noviembre 2014.
54. Casos difíciles. Conferencista, NAF Congreso Regional Latinoamericano, Bogotá, Colombia. 7 Noviembre 2014.
55. Mecanismo de acción del Dispositivo intrauterino hormonal y el implante subdérmico. NAF Congreso Regional Latinoamericano, Bogotá, Colombia. 7 Noviembre 2014.
56. Estándares para la prestación de servicios de aborto: Guías Clínicas de NAF. NAF Congreso Regional Latinoamericano, Bogotá, Colombia. 7 Noviembre 2014.
57. Ultrasound Principles & Practice for Second Trimester Pregnancies. NAF Regional Workshop, Cleveland, OH. October 20, 2014.
58. Dilation and Evacuation Workshop. Invited Speaker, FIAPAC Congress 2014, Ljubljana, Slovenia. October 2, 2014.
59. Hands-on Ultrasound Training. NAF Canadian Regional Workshop, Vancouver, BC. September 14, 2014.
60. Pregnancy of Unknown Location. NAF Canadian Regional Workshop, Vancouver, BC. September 13, 2014.
61. Serious Complications. NAF Canadian Regional Workshop, Vancouver, BC. September 13, 2014.
62. El Futuro de la Anticoncepción. Invited Speaker, 29th Congreso Nacional de Obstetricia y Ginecología. Federación Colombiana de Obstetricia y Ginecología (FECOLSOG), Medellín, Colombia. 30 May 2014.
63. Implantes Anticonceptivos. Invited Speaker, 29th Congreso Nacional de Obstetricia y Ginecología. Federación Colombiana de Obstetricia y Ginecología (FECOLSOG), Medellín, Colombia. 30 May 2014.

## Curriculum Vitae

Matthew F. Reeves, MD, MPH

64. Termination of Pregnancy in the Second Trimester. Invited Speaker, 29th Congreso Nacional de Obstetricia y Ginecología. Federación Colombiana de Obstetricia y Ginecología (FECOLSOG), Medellín, Colombia. 29 May 2014.
65. ¿Se necesita el uso rutinario de ultrasonido obligatorio en la atención del aborto con medicamentos? Invited Speaker, Optimizando el Potencial de los Medicamentos en la Interrupción del Embarazo en Sudamérica. Gynuity Health Project, Lima, Perú. 9-10 May 2014.
66. The use of antibiotics at abortion: When less is more. Post-Graduate Seminar: Re-Evaluating Pre-Procedure Preparation and Evaluation. NAF 38th Annual Meeting, San Francisco, CA. 6 April 2014.
67. Evaluating Potential Placenta Accreta. Post-Graduate Seminar: Re-Evaluating Pre-Procedure Preparation and Evaluation. NAF 38th Annual Meeting, San Francisco, CA. 6 April 2014.
68. Orientación al Ecografía. Training; Oriéntame, Bogotá, Colombia. 22-23 October 2013.
69. Implantes Anticonceptivos. Invited Speaker; ESAR Ecuador Annual Meeting, Guayaquil, Ecuador. 19 October 2013.
70. Working in Women's Global Health: Lessons Learned from the Field. North American Forum on Family Planning, Seattle, WA. October 7, 2013.
71. The Use of Antibiotics at Medication Abortion. Invited Speaker; PPFA National Medical Conference, Seattle, WA. October 4, 2013.
72. Hands-On Ultrasound Training for First-trimester Gestational Dating. Invited Speaker; Reproductive Health 2013, Denver, CO. September 19, 2013.
73. Orientation to Ultrasound with Hands-on Practice. Invited Speaker, NAF Annual Meeting, New York, NY. April 27, 2013.
74. Prevention of Infection after Abortion. Invited Speaker, PPFA Medical Directors Council (MeDC) 9th Annual Clinical Meeting, Miami. March 2, 2013.
75. Ultrasound Following Medical Abortion. Invited Speaker, FIAPAC Congress 2012, Edinburgh. October 20, 2012.
76. Progress in the Implementation of Global and National PPH Prevention Programs. Invited moderator, FIGO World Congress of Gynecology and Obstetrics, Rome. October 10, 2012.
77. Use of MVA in abortion before 7 weeks. Speaker, Expanding manual vacuum aspiration (MVA) training and competence panel; FIGO World Congress of Gynecology and Obstetrics, Rome. October 9, 2012.
78. Ultrasound after Medical Abortion: Uses and Limitations. Speaker, Methods of Assessing Medical Abortion Outcome: High Technology to No Technology panel; FIGO World Congress of Gynecology and Obstetrics, Rome. October 9, 2012.
79. MVA Hands-On Workshop. Workshop Leader; Reproductive Health 2012, New Orleans, LA. September 22, 2012.
80. Introduction to First-trimester Ultrasound for Gestational Dating and IUD Location. Invited Speaker; Reproductive Health 2012, New Orleans, LA. September 20, 2012.
81. Ultrasound in First Trimester. Invited Speaker; NAF Risk Management Conference. Mexico City, Mexico, September 11, 2012.
82. Ultrasound in Abortion Care. Invited Speaker: Basics of Second-Trimester Abortion Workshop. NAF Annual Meeting, Vancouver, BC. April 21, 2012.
83. Use of Essure in Women with Hydrosalpinges. Invited Speaker; Aegean Gynecological Endoscopy Symposium, Izmir, Turkey. April 19, 2012.
84. Which Test and When? Implications for Improving Access to Safer Medical Abortion Service Delivery Globally. Invited Speaker; Paving the Path for Semi-Quantitative Pregnancy Test to Reduce the Need for Clinic-Based Follow-up after Medical Abortion, Los Altos, CA. February 14, 2012.
85. A Hysteroscopic Approach to Permanent Contraception. Invited Speaker; Korle Bu Hospital Department of Obstetrics & Gynecology, Accra, Ghana. December 15, 2011.
86. Post-Abortal Provision of Long-acting Reversible Contraception: A Review of the Evidence and its Implications. Session chair; International Conference on Family Planning, Dakar, Senegal. November 30, 2011.
87. The potential impact of LARC after abortion: A decision analysis. Invited Speaker; International Conference on Family Planning, Dakar, Senegal. November 30, 2011.
88. Public-Private Partnerships. Invited Speaker; Multipurpose Prevention Technologies for Reproduction Health Symposium, Washington, DC. November 4, 2011.

## Curriculum Vitae

Matthew F. Reeves, MD, MPH

89. Biodegradable Implants. Invited Speaker; Future of Contraception Initiative, Seattle, WA. October 31, 2011.
90. Predictors of Uterine Evacuation after Medical Abortion. Invited speaker; Medical Abortion Follow-up from No Tech to High Tech plenary session, North American Forum on Family Planning, Washington, DC. October 23, 2011.
91. Working Group 2: Ultrasound Services. Invited speaker/advisor; PPF National Medical Committee, North American Forum on Family Planning, Washington, DC. October 21, 2011.
92. LARC Insertion Post-Abortion. Invited speaker; CAPS meeting, North American Forum on Family Planning, Washington, DC. October 21, 2011.
93. Long-Acting Reversible Contraception: Recent Research. Invited speaker; NAF Risk Management Meeting, New Orleans, LA. October 16, 2011.
94. Ultrasound 101. Invited speaker; Reproductive Health 2011, Las Vegas, NV. September 15, 2011.
95. Manual Vacuum Aspiration Case Study: Zimbabwe. Invited speaker; Annual Membership Meeting, Reproductive Health Supplies Coalition. Addis Ababa, Ethiopia, 24 June 2011.
96. Using Ultrasound in Medical Abortion Follow Up. Invited speaker; 13th Annual Mifepristone Medical Abortion Meeting, Gynuity Health Projects, New York, NY. June 6, 2011.
97. Management of Medical Abortion Follow Up. Invited speaker; Medical Abortion Post-Graduate Seminar, NAF Annual Meeting, Chicago, IL. April 10, 2011.
98. Applications of Ultrasound in Second Trimester. Invited speaker; Induction, Hybrid, and Later Abortion Care. Pre-Conference Workshop, NAF Annual Meeting, Chicago, IL. April 9, 2011.
99. How Research Guides Clinical Practice. Invited panelist; Reproductive Health 2010, Atlanta, GA. Sept. 25, 2010.
100. Proof of Concept in Microbicides: Prevention of HIV & HSV by Tenofovir gel in the CAPRISA 004 study. Invited speaker; Reproductive Health 2010, Atlanta, GA. September 24, 2010.
101. 50 Years of the Pill: Revolutionizing Health and Dispelling Myths. Invited panelist; Society for Women's Health Research, Rayburn House Office Building, Washington, DC. September 21, 2010.
102. Long-acting Contraception – First-Year Fellows' Small Group Research Presentations. Invited moderator; FFP Annual Meeting, San Francisco. May 15, 2010
103. Contraception Update: Post-Abortal Contraception. Invited speaker; NAF Annual Meeting, Philadelphia, PA. April 26, 2010
104. Applications of Ultrasound in Second Trimester. Invited speaker; Advanced Second-Trimester Workshop, NAF Annual Meeting, Philadelphia, PA. April 24, 2010
105. Understanding Ultrasound. Invited Speaker; Combined Grand Rounds, Washington Hospital Center & Georgetown University Medical Center, Washington, DC. January 21, 2010.
106. Free Communication Session – Oral Presentations: Contraception. Invited chairperson; XIX FIGO World Congress of Gynecology and Obstetrics. Cape Town, South Africa. October 5, 2009.
107. Should Antibiotics Be Used Routinely for Medical and Surgical Abortion? Invited Panelist; Reproductive Health 2009. Los Angeles, CA. October 1, 2009.
108. International Work in an Academic Institution. Invited Speaker; Fellowship in Family Planning International Workshop. Los Angeles, CA. September 30, 2009
109. Post-abortal Insertion of Intrauterine Devices. Invited Speaker; Grand Rounds. Department of Obstetrics & Gynecology, Tulane University School of Medicine. May 15, 2009
110. Basics of Second-Trimester Surgical Abortion. Invited speaker; Second-Trimester Surgical Abortion workshop, NAF Annual Meeting, Portland, OR. April 24, 2009.
111. Applications of Ultrasound in Second Trimester. Invited speaker; Second-Trimester Surgical Abortion workshop, NAF Annual Meeting, Portland, OR. April 24, 2009.
112. Update on Ectopic Pregnancy: Cesarean Scar Ectopic Pregnancy and Sonographically Guided Injection Treatment of Ectopic Pregnancy. Invited speaker; NAF Annual Meeting, Portland, OR. April 25, 2009.
113. The Modern Era of Contraception. Invited speaker; First Unitarian Universalist Church of Pittsburgh. March 29, 2009.
114. Improving Contraception in Microbicide Trials. Invited speaker; Conference on Pregnancy and Contraception in Microbicide Development. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD. March 9, 2009.



## Curriculum Vitae

Matthew F. Reeves, MD, MPH

115. Highly Effective Contraception. Guest Lecturer; Queen Elizabeth Central Hospital, Blantyre, Malawi. 12 February 2009.
116. Copper Intrauterine Devices. Guest Lecturer; Queen Elizabeth Central Hospital, Blantyre, Malawi. 11 February 2009.
117. Copper Intrauterine Devices. Guest Lecturer; Mulanje Mission Hospital, Mulanje, Malawi. 10 February 2009.
118. Understanding Ultrasound. Global Health Lecture, Department of Medicine, University of Pittsburgh. Pittsburgh, PA, December 10, 2008.
119. Conducting Research in the Developing World. Planning and Implementing a Research Initiative Abroad. Global Health Seminar, Magee-Womens Hospital, University of Pittsburgh School of Medicine. November 19, 2008.
120. Understanding Ultrasound. Invited Lecturer; NAF Risk Management Conference. Halifax, Nova Scotia, October 19, 2008.
121. Invited discussant for oral presentation; Reproductive Health 2008. Washington, DC, September 18, 2008.
122. Ultrasound Training Seminar: Placenta Localization and Ovarian Identification. Chief Faculty; PPFA National Medical Committee Meeting, Washington, DC, September 17, 2008.
123. Colposcopy for the Evaluation of Vaginal Products. Training Workshop Leader; Centro de Estudios de Materno-Infantiles, Universidad de Puerto Rico. August 28-29, 2008.
124. Long-Term Contraception. Invited speaker; University of Pittsburgh Student Health. August 22, 2008
125. Colposcopy for the Evaluation of Vaginal Products. Trainer; Hope Clinic, Emory University. June 25, 2008. [half-day training workshop]
126. Sonographic Endometrial Thickness. Reproductive Endocrinology Conference, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh School of Medicine. June 2, 2008.
127. Long-Term Contraception. Invited speaker; Women's Health Seminar Series, Division of General Internal Medicine, University of Pittsburgh. Montefiore Hospital, Pittsburgh, PA, May 12, 2008
128. Applications of Ultrasound in Second Trimester. Invited speaker; NAF Annual Meeting, Minneapolis. April 5, 2008
129. Family Planning in the International Setting. Medical Students for Choice & Global Health Interest Group, University of Pittsburgh School of Medicine. February 20, 2008.
130. Ultrasonography in the First Trimester. Resident Education Conference, Magee-Womens Hospital. August 17, 2007
131. Ultrasonographic Diagnosis of Ectopic Pregnancy. Resident Education Conference, Magee-Womens Hospital. August 17, 2007
132. Post-Abortal Insertion of Intrauterine Devices. Invited Speaker, Grand rounds, Department of Obstetrics & Gynecology, West Virginia University School of Medicine. June 28, 2007.
133. Lessons for Graduating Fellows. Invited Panelist, Family Planning Fellowship Annual Meeting, San Diego. May 6, 2007.
134. Intrauterine Contraception Symposium. Co-Chair, Family Planning Fellowship Annual Meeting, San Diego. May 4, 2007.
135. Talking to Patients and Dispelling Myths about Intrauterine Contraception. Invited speaker, Intrauterine Contraception Symposium. Family Planning Fellowship Annual Meeting, San Diego. May 4, 2007
136. Non-Contraceptive Uses of Levonorgestrel-Releasing Intrauterine Devices. Invited speaker, Intrauterine Contraception Symposium. Family Planning Fellowship Annual Meeting, San Diego. May 4, 2007
137. Intrauterine Contraception in Patients with Complex Medical Problems. Invited speaker, Intrauterine Contraception Symposium. Family Planning Fellowship Annual Meeting, San Diego. May 4, 2007
138. Opportunities for Outreach, Training, and Research. Invited speaker, Intrauterine Contraception Symposium. Family Planning Fellowship Annual Meeting, San Diego. May 4, 2007
139. Medical Abortion Regimens. Reproductive Endocrinology Conference, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh School of Medicine. April 9, 2007.
140. The Evolution of Medical Abortion. Grand Rounds, Department of Obstetrics & Gynecology, University Hospitals, Case Western Reserve University. March 23, 2007.

141. Colposcopy for the Evaluation of Vaginal Products. Trainer, Centro de Estudios de Materno-Infantiles, Universidad de Puerto Rico. March 15, 2007. [One-day training workshop]
142. Invited Speaker, "Contraception." Your Health radio broadcast, WRCT 88.3 FM. Carnegie-Mellon University, Pittsburgh, PA. March 6, 2007.
143. Sonographic Assessment of the Endometrium. Ultrasound Grand Rounds, Magee-Womens Hospital, University of Pittsburgh, January 31, 2007.
144. Implanon: The New Contraceptive Implant. Grand Rounds, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh, September 12, 2006.
145. Post-Abortal Insertion of Intrauterine Devices: A Contraceptive Decision Analysis Grand Rounds,. Department of Obstetrics and Gynecology, David Geffen School of Medicine at the University of California-Los Angeles, May 26, 2006.
146. The Public Health Impact of Increased Access to Intrauterine Devices. Magee-Womens Research Institute Postdoctoral Fellowship Research Day. May 16, 2006.
147. Contraceptive Implants: Implanon. Grand Rounds, Dept of Obstetrics & Gynecology, Women's and Children's Hospital of Buffalo, University of Buffalo. April 19, 2006.
148. Permanent Surgical Sterilization: Effectiveness & Safety. Grand Rounds, Dept of Obstetrics & Gynecology, Women's and Children's Hospital of Buffalo, University of Buffalo. April 19, 2006.
149. The Cost-Effectiveness of Antibiotic Use at Abortion. Gynecologic Specialties Conference, Magee-Womens Hospital. April 14, 2006.
150. Contraception and Family Planning in Vietnam. Gynecologic Specialties Conference, Magee-Womens Hospital. March 3, 2006.
151. Ultrasonography in the First Trimester. Project Vietnam Lecture Series, Binh Duong District Hospital, Binh Duong, Vietnam. January 26, 2006.
152. Sonographic Assessment of Fetal Anatomy. Project Vietnam Lecture Series, Binh Duong District Hospital, Binh Duong, Vietnam. January 26, 2006.
153. Sonographic Assessment of Fetal Wellbeing. Project Vietnam Lecture Series, Binh Duong District Hospital, Binh Duong, Vietnam. January 26, 2006.
154. The Diagnosis and Management of Ectopic Pregnancy. Project Vietnam Lecture Series, Binh Duong District Hospital, Binh Duong, Vietnam. January 19, 2006.
155. Methods of Cervical Dilatation. Post-Graduate Course in Obstetrics & Gynecology, Tu Du Hospital, Ho Chi Minh City, Vietnam. January 18, 2006.
156. The Diagnosis and Management of Ectopic Pregnancy. Post-Graduate Course in Obstetrics & Gynecology, Tu Du Hospital, Ho Chi Minh City, Vietnam. January 11, 2006.
157. Ultrasonography in the First Trimester. Post-Graduate Course in Obstetrics & Gynecology, Tu Du Hospital, Ho Chi Minh City, Vietnam. January 4, 2006.
158. Antibiotic Use at Abortion. Post-Graduate Course in Obstetrics & Gynecology, Tu Du Hospital, Ho Chi Minh City, Vietnam. December 28, 2005.
159. Post-Abortal Insertion of Intrauterine Devices: A Decision Analysis. Monthly Modeling Meeting, Section of Decision Sciences and Clinical Systems Modeling, Division of General Internal Medicine, University of Pittsburgh School of Medicine. November 8, 2005.
160. Post-Abortion Insertion of Intrauterine Devices: Future Directions. Gynecologic Specialties Conference, Magee-Womens Hospital. October 14, 2005.
161. Complications of Mifepristone: Infections & Pharmacogenetics. Reproductive Health 2005 Conference. Associate of Reproductive Health Professionals/Society for Family Planning, Tampa, FL. September 10, 2005.
162. The Effects of Mifepristone on Steroid Hormone Systems: More than Just an Anti-Progestin. Gynecologic Specialties Conference, Magee-Womens Hospital. July 29, 2005.
163. Method of Cervical Dilatation. Gynecologic Specialties Conference, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital. July 1, 2005.
164. Reading the Medical Literature. Family Planning Conference, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital. April 25, 2005.

165. Contraception and Breast Cancer. Family Planning Conference, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital. May 23, 2005.
166. Antibiotic Use at Family Planning Procedures. Family Planning Conference, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital. March 14, 2005.
167. A Cost-Effectiveness Analysis of Antibiotic Use at Abortion. Monthly Modeling Meeting of the Section of Decision Sciences and Clinical Systems Modeling, Division of General Internal Medicine, University of Pittsburgh School of Medicine. March 8, 2005.
168. Alternative Methods of Sterilization: Quinacrine & Methods in Development. Family Planning Conference, Magee-Womens Hospital. February 14, 2005.
169. Non-Contraceptive Uses of Levonorgestrel-Releasing Intrauterine Devices. Family Planning Conference, Magee-Womens Hospital. January 10, 2005.
170. Contraceptive Implants: The Arrival of Implanon. Family Planning Conference, Magee-Womens Hospital. December 13, 2004.
171. Permanent Surgical Sterilization: A Review of Effectiveness & Safety. Family Planning Conference, Magee-Womens Hospital. November 8, 2004.
172. Post-Abortion Insertion of Intrauterine Devices: A Review of 33 years of Evidence. Family Planning Conference, Magee-Womens Hospital. October 4, 2004.
173. Ultrasonography in the First Trimester. Family Planning Conference, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital. August 16, 2004.
174. Limited Obstetric Ultrasonography. Seminar, St. Luke's Women's Center. January 24, 2004.
175. Post-Abortion Insertion of Intrauterine Devices: A Review of the Evidence and Our Experience. Grand Rounds, UCSF Department of Obstetrics, Gynecology, and Reproductive Sciences. June 12, 2003.

---

## TEACHING & MENTORING ACTIVITIES

---

### Research mentoring for family planning fellows at Washington Hospital Center:

- Frances Casey, MD MPH. Fellowship Research Project Mentor, 2011-13: "A Randomized Double-blinded Comparison of Same-Day Mifepristone and Misoprostol with Misoprostol only for Cervical Preparation in Second-Trimester Surgical Abortion."
- Peggy Ye, MD MPH. Fellowship Research Project Mentor, 2012-14: "Assessing Barriers to Post-Abortal LARC Provision through Qualitative Interviews"
- Jamilah Shakir, MD, MPH. Fellowship Research Project Mentor, 2013-15: "A Factorial-Design Randomized Controlled Trial Comparing Misoprostol alone to Dilapan with Misoprostol and Comparing Buccal to Vaginal Misoprostol for Same-day Cervical Preparation prior to Dilation & Evacuation"
- Diane Horvath-Cosper, MD, MPH. Fellowship Research Project Mentor, 2014-16: "A randomized controlled trial of three prophylactic antibiotic regimens for first-trimester surgical abortion"
- Ashley Brant, DO, MPH. Fellowship Research Project Mentor, 2016-18: "Gabapentin as an adjunct for pain management during dilation and evacuation: A double-blind randomized controlled trial"

### Research mentoring for students at Johns Hopkins Bloomberg School of Public Health:

- Erika L. Boothman, 2014-15. Use of ultrasonography at intrauterine contraceptive insertion.
- Jessica A. Monmaney, 2014-15. Predictors of uterine aspiration after medical abortion.

### Advising & mentoring residents at Magee-Womens Hospital and the University of Pittsburgh:

- Madeleine Courtney-Brooks, MD. Internship/Residency Advisor 2006-2010.
- Michelle Moniz, MD. Internship/Residency Advisor 2008-2010.
- Susan Lareau, MD. Advisor for Grand Rounds: "Maternal Mortality in the Developing World." July 10, 2007.

## Curriculum Vitae

Matthew F. Reeves, MD, MPH

- Catherine Hilliker, MD. Advisor for Grand Rounds: "Management of Abnormal Ovarian Cysts." August 28, 2007.

Research mentoring for residents at Magee-Womens Hospital and the University of Pittsburgh:

- Sarah Hutchison, MD. Residency Research Project Advisor, 2006-2009: "Predictors of Late Presentation for Elective Abortion at Magee-Womens Hospital." oral presentation, 2008 Hayashi Research Day
- Steven Tobia, MD. Residency Research Project Advisor, 2007-2008: "A Meta-Analysis of Post-Abortal IUD Insertion." Oral presentation, 2008 Hayashi Research Day
- Erin Cook, MD. Residency Research Project Advisor, 2007-2009: "Patient perceptions of long-term contraceptives and predictors in method selection." Oral presentation, 2009 Hayashi Research Day
- Madeleine Courtney-Brooks, MD. Residency Research Project Advisor, 2007-2010: "Endometrial thickness greater than 15 mm in menstruating women" Oral presentation, 2009 Hayashi Research Day
- Gregory Mallek, MD. Residency Research Project Advisor, 2009: "Risk factors for Cesarean scar ectopic pregnancy, a case-control study." Poster presentation, 2009 Hayashi Research Day
- Amber Samuel, MD. Residency Research Project Advisor, 2008-2009: "Outcomes of Cesarean scar implantation." Poster presentation, 2009 Hayashi Research Day
- Rachel Becker Rapkin, MD MPH. Residency Research Project Advisor, 2008-2010: "Indicators of poor outcomes in early first-trimester sonograms." Oral presentation, 2010 Hayashi Research Day

Advising & mentoring University of Pittsburgh medical students:

- Anupa Kudva, class of 2009. Scholarly Project Advisor, 2006-2008: "Medical abortion outcomes after second-dose misoprostol: Is the presence of cardiac motion on follow-up ultrasound predictive of failure?"
- Tiffany Behringer, class of 2011. Clinical Scientist Training Program Mentor, 2007-2009: "Needs and desires of contracepting women in Pittsburgh."

---

INTERNATIONAL ACTIVITIES

---

University of Ibadan, Ibadan, Nigeria Undergraduate Junior Year Abroad	October 1991-April 1992
University of Nagoya, Nagoya, Japan Monbusho fellow, with Professor Gen Sobue	June-August 1996
Holy Family Hospital, Phalombe, Malawi Two-month sub-internship in women's health.	February-March 1998
Holy Family Hospital, Phalombe, Malawi Two-week clinical rotation.	October 2000
Tu Du Maternity Hospital, Ho Chi Minh City, Vietnam University of Medicine and Pharmacy, at Ho Chi Minh City: Family planning education & research Binh Duong District General Hospital: Gynecologic and obstetric ultrasound education	December 2005-February 2006
Hôpital Albert Schweitzer, Des Chapelles & Hôpital La Lumière, Les Cayes, Haiti Site evaluation for Magee-Womens Hospital residency	November 2007
University of Malawi College of Medicine, Blantyre, Malawi Site visit for Partnerships in Education and Excellence in Reproductive Health	March 2008
University of Malawi College of Medicine, Blantyre, Malawi Contraceptive education and training	February 2009
Gonjoni clinic, Mombasa, Kenya	February 2009



## Curriculum Vitae

Matthew F. Reeves, MD, MPH

Trainer for course in colposcopy for the evaluation of vaginal products	
Georgetown Public Hospital & University of Guyana, Georgetown, Guyana	March 2009
Site evaluation for Magee-Womens Hospital residency	
WomanCare Global Training for Essure Permanent Contraception	
Istanbul, Turkey	April 2011
Mexico City, Mexico	May 2011
Nairobi, Kenya	June 2011
Accra, Ghana	December 2011
Izmir, Turkey	April 2012
WomanCare Global Training for Levoplant/Simplant Contraceptive Implant	
Santiago, Chile	June 2012
Santiago, Chile	March 2013
Nantes, France	October 2018
Kigali, Rwanda	November 2018
WomanCare Global Mifepristone Launch	
Kisumu, Kenya	January 2013
NAF Site Evaluations and Training	
Fundación Oriéntame, Bogotá, Colombia	July 2013
Fundación Si Mujer, Cali, Colombia	November 2013
Fundación Oriéntame, Bogotá, Colombia	October 2013
Marie Stopes México, Distrito Federal, México	March 2014
Femisana Women's Center, Distrito Federal, México	June 2015
Ministry of Health clinics, Ciudad de México, México	February 2016
CIPA, Ciudad de México, México	June 2016
Gineclinic, Ciudad de México, México	August 2017
Hospital La Florida, Santiago, Chile	December 2017
APROFA, Santiago, Chile	September 2018
Maternal-Child Survival Program Zika Ultrasound Evaluation	
República Dominicana, 4 sites	March 2017
DKT WomanCare Training for Iupas uterine aspirators	
Kigali, Rwanda	November 2018
Nagoya, Japan	April 2019
Tokyo, Japan	April 2019

---

OTHER TRAINING & EDUCATION

1. Hopkins HIPAA Patient Privacy for Workforce Members, completed July 24, 2020.
2. Hopkins Electronic Information Security and Data Management Training, completed July 24, 2020.
3. Maintenance of Certification, American Board of Obstetrics and Gynecology, completed annually 2013-2020.
4. Health Insurance Portability and Accountability Act (HIPAA) training. ProHIPAA. July 24, 2019.
5. Hopkins HIPAA Patient Privacy Training for Workforce Members, completed March 9, 2018.
6. Hopkins Electronic Information Security and Data Management Training, completed March 9, 2018.
7. CITI Investigators and Research Personnel (non-CRC/CRP), completed June 26, 2017.
8. CITI Good Clinical Practice Course, completed June 12, 2017 .

Curriculum Vitae

Matthew F. Reeves, MD, MPH

9. Excellence in Family Planning Research, January 31-February 5, 2014. Taught by Drs. David Grimes and Ken Schultz.
10. CITI Investigators and Research Personnel (non-CRC/CRP), completed October 30, 2013.
11. CITI Basic Biosafety Training, completed October 30, 2013.
12. CITI Biomedical Responsible Conduct of Research, completed July 15, 2012.
13. CITI Good Clinical Practice Course, completed July 15, 2012.
14. Advanced Modeling Methods for Economic Evaluation. Simon Fraser University, Vancouver, July 23-25, 2008. Taught by Drs. Karl Klaxton and Andy Briggs.
15. CITI Good Clinical Practice Course, completed April 10, 2008.
16. CITI Human Research Curriculum, completed April 9, 2008.
17. FHI Good Clinical Practice Workshop, November 29, 2007.
18. UPMC Training Certificate on Investigational Device Exemptions, completed January 16, 2007.
19. NIH Human Participants Protection Education for Research Teams, completed November 17, 2006.
20. Course in Scientific Leadership and Management, University of Pittsburgh, March 30-31, 2006.
21. Policy, Advocacy, Legislation, & Media (PALM) workshop, Washington, DC, September 25-26, 2005.
22. UCSF Human Subject Protections Basic Course, completed September 2, 2003.
23. CREOG Workshop for Obstetrics & Gynecology Chief Residents, New York, April 19-21, 2002.